| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Photodynamic Therapy (PDT) | Oncology | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Photodynamic Therapy (PDT) | Oncology | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Photodynamic Therapy (PDT) | Oncology |
Recent Updates
Recently added Catalysts
Soligenix, Inc.$0.36
-0.01 (-2.17%)
C 41Pipeline Score Fair Value Pharma · Clinical
Market Cap
5.78 M
EPS
-1.97
P/E Ratio
-
Value Trade
3.64 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
1.78 M
Operating CF
-2.36 M
Total Assets
6.92 M
Total Liabilities
3.83 M
Equity
3.09 M
D/E Ratio
12,345
-1.71 %
Week
-70.67 %
1 Month
-65.17 %
3 Month
-69.04 %
6 Month
-99.84 %
5 Year
-100 %
All Time
Cash Data
Cash Position
6.03 M
Monthly Burn
786.00 K
Runway
5.6 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
269.80 K
52 Week Range
0.28 - 6.23
% held by Insiders
6.74 %
% held by Institutions
1.76 %
Enterprise Value
84.14 K
Total Shares
14.83 M
Short %
2.85 %
Float Shares
14.35 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Soligenix, Inc.
1054Total events
6Upcoming
244Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 6
TBD
T2Timing Guidance
Plan to embark on reformulation for home-based subcutaneous injection and interact with health authorities for follow-on study
2026-H2
T1Topline Readout
Top-line results from confirmatory Phase 3 FLASH2 trial of HyBryte™ for CTCL
2026-H2
T2Trial Initiation
Initiate placebo-controlled Phase 2 study of SGX945 (dusquetide) for Behçet's Disease
TBD
T2FDA Feedback Received
Planned interaction with health authorities for follow-on placebo-controlled Phase 2 study design
Event history 1048
Jun 12, 2026
◆Other Regulator MilestoneEx-US Regulatory
Application for CEPI funding for Bundibugyo virus vaccine development due
Bundibugyo virus vaccinesource ↗
Apr 28, 2026
▼Trial Stopped FutilityHyBryte™Trial
Phase 3 FLASH2 trial halted for futility after interim efficacy analysis
cutaneous T-cell lymphomasource ↗
Apr 28, 2026
▼Interim AnalysisHyBryte™Trial
Interim efficacy analysis completed by Data Monitoring Committee
cutaneous T-cell lymphomasource ↗
Apr 2, 2026
▲PublicationHyBryte™Presentation
Positive results of comparability study of HyBryte vs Valchlor published in Oncology and Therapy
cutaneous T-cell lymphomasource ↗
Apr 2, 2026
●PublicationHyBryte™Presentation
Comparability study of HyBryte vs Valchlor published in Oncology and Therapy
cutaneous T-cell lymphomasource ↗
Q2 2026
◆Interim AnalysisHyBryte™Trial
Pre-specified blinded interim analysis of FLASH2 study expected
cutaneous T-cell lymphomasource ↗
Apr 2026
▼Trial DiscontinuedHyBryte™Trial
FLASH2 trial halted for futility after interim analysis
cutaneous T-cell lymphomasource ↗
Apr 2026
▼Interim AnalysisHyBryte™Trial
Interim efficacy analysis completed by Data Monitoring Committee
cutaneous T-cell lymphomasource ↗
Q2 2026
◆Timing GuidanceHyBryte™Presentation
Topline results expected in second half of 2026 for confirmatory Phase 3 trial of HyBryte in CTCL
early-stage cutaneous T-cell lymphoma (CTCL)source ↗
Q2 2026
◆Topline ReadoutHyBryte™Clinical Data
Top-line results from confirmatory Phase 3 CTCL trial anticipated in second half of 2026
cutaneous T-cell lymphoma (CTCL)source ↗
Drug Pipeline Intelligence
C41
Pipeline Score $9M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored1.6x
rNPV / MCap Top 58%
Micro Cap (rank 384 of 912)
Percentile RankSoligenix, Inc. carries a moderate pipeline score (41/100), with $1.5B risk-adjusted pipeline value, led by Hypericin in Psoriasis (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypericin Small molecule | CTCL/ Mycosis Fungoides | Phase 3 | NCT06470451 | 42% | $960M | RECRUITING | 80 | STALLED | B (65) | Oct 1, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
HyBryte™ Fast TrackOrphan | cutaneous T-cell lymphoma | Phase 3 | 2026-04-28 | the study was recommended to halt for futility | Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma Read More | |
HyBryte™ Fast TrackOrphan | cutaneous T-cell lymphoma | Phase 3 | 2026-04-28 | the study was recommended to halt for futility | Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma Read More | |
HyBryte™ Fast TrackOrphan | cutaneous T-cell lymphoma | Phase 3 | 2026-04-28 | the study was recommended to halt for futility | Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SNGX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SNGX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SNGXSoligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Soligenix, Inc. is applying for funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a thermostable vaccine for the Bundibugyo virus. The company has previously shown promising results with its vaccine platform, demonstrating robust immune responses and protection in non-human primates. However, the success of the funding application remains uncertain, especially following the discontinuation of another clinical trial.
Read more →SNGX▲ +31.5%on this news· ran to +133% by day 3
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
Soligenix, Inc. is advancing a thermostable vaccine for the Bundibugyo virus, which is linked to the recent outbreak in Congo. Collaborating with Dr. Axel Lehrer, the company has demonstrated the vaccine's efficacy in preclinical studies. The platform aims to simplify vaccine distribution in endemic areas, but its development hinges on securing adequate funding.
Read more →SNGXSoligenix Announces Recent Updates and First Quarter 2026 Financial Results
Soligenix, Inc. reported disappointing results from its FLASH2 study, leading to a halt for futility. Despite initial success with HyBryte™, the extended treatment did not yield expected results. The company is evaluating strategic options, including potential mergers and advancing other therapies like SGX945 for Behçet's Disease. Financially, Soligenix reported a net loss of $2.8 million for Q1 2026.
Read more →SNGX▼ -70.3%on this news
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. announced that the Phase 3 FLASH2 trial of HyBryte™ for cutaneous T-cell lymphoma was halted due to an interim analysis indicating futility. Despite previous success in a related study, the current trial did not show expected efficacy after 18 weeks. The company plans to analyze the data further and explore potential next steps, including discussions with regulatory agencies.
Read more →SNGXPositive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Soligenix, Inc. announced positive results from a comparability study of HyBryte™ against Valchlor® for treating cutaneous T-cell lymphoma (CTCL). The study, published in Oncology and Therapy, showed that 60% of HyBryte™ patients achieved treatment success compared to 20% for Valchlor®. HyBryte™ was well tolerated, with no adverse events reported, highlighting its potential as a safer alternative for CTCL treatment.
Read more →SNGX▲ +6.3%on this newsshared move
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Soligenix, Inc. reported its financial results for 2025, highlighting key milestones and upcoming clinical trials. The company anticipates interim analysis results from the Phase 3 FLASH2 trial of HyBryte™ for CTCL in Q2 2026. Additionally, dusquetide received orphan drug designation for Behçet's Disease, while SGX302 showed clinical benefits in psoriasis. However, the company faced a net loss of $11.1 million and no revenues for the year.
Read more →SNGXSoligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
Soligenix, Inc. has been granted orphan drug designation for SGX945 by the European Commission for the treatment of Behçet's Disease. This designation follows positive Phase 2a clinical trial results showing efficacy and safety. The orphan designation provides marketing exclusivity in the EU and aids in product development support. The company aims to address the unmet medical needs of patients suffering from this chronic condition.
Read more →SNGXHyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
Soligenix, Inc. announced that findings from trials of HyBryte™ for cutaneous T-cell lymphoma will be presented at the US Cutaneous Lymphoma Consortium Workshop. The results indicate positive outcomes in comparison to Valchlor® and highlight the treatment's efficacy and safety. Dr. Ellen Kim will present the findings, showcasing the potential of HyBryte™ as a long-term treatment option.
Read more →SNGXSoligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Soligenix, Inc. announced the publication of a clinical summary for HyBryte™ in 'Expert Opinion on Investigational Drugs'. The summary details positive results from clinical trials for treating cutaneous T-cell lymphoma (CTCL). Dr. Poligone emphasizes HyBryte™'s unique mechanism and safety profile, while Soligenix looks forward to completing patient enrollment in the ongoing FLASH2 Phase 3 study.
Read more →SNGXSoligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
Soligenix, Inc. announced that SGX945 (dusquetide) has received the Promising Innovative Medicine designation from the UK's MHRA for treating Behçet's Disease. This designation is a prerequisite for inclusion in the Early Access to Medicines Scheme, which allows severely ill patients to access new medicines earlier. Clinical studies have shown that SGX945 is likely to offer major advantages over existing treatment methods for Behçet's Disease. The company aims to leverage this designation to expedite the availability of SGX945 to affected patients.
Read more →SNGXSoligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
Soligenix, Inc. announced that the European Medicines Agency's Committee for Orphan Medicinal Products provided a positive recommendation for orphan drug designation of SGX945 for Behçet's Disease. This follows promising Phase 2a clinical results showing efficacy and safety. The next step is ratification by the European Commission, which could enhance market exclusivity in the EU.
Read more →SNGXSoligenix to Present at BIO Investment & Growth Summit
Soligenix, Inc. announced that its CEO, Dr. Christopher J. Schaber, will present at the BIO Investment & Growth Summit on March 2. The summit will feature various programs and meetings aimed at fostering investment in biopharmaceutical innovations. Soligenix is focused on developing treatments for rare diseases and has several ongoing clinical programs.
Read more →SNGXSoligenix Details Recent Progress and Upcoming Milestones
Soligenix, Inc. provided an update on its late-stage pipeline and strategic options for 2026. The company anticipates significant sales from its products, particularly HyBryte™, with a projected market opportunity exceeding $90 million in the U.S. However, it faces uncertainties regarding clinical trial outcomes and regulatory approvals.
Read more →SNGXSoligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Soligenix, Inc. announced positive top-line results from its Phase 2a study of SGX302 for mild-to-moderate psoriasis. The optimized gel formulation demonstrated clinical success, with patients showing significant improvements in psoriasis severity indices. The treatment was well tolerated, indicating its potential as a safe option for psoriasis management.
Read more →SNGXPositive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet
Soligenix, Inc. has announced positive results from a Phase 2a study of SGX945 for treating Behçet's disease. The study revealed that SGX945 effectively reduced oral ulcers in seven out of eight patients, with benefits reportedly lasting beyond the treatment period. The results compared favorably to a Phase 3 trial of apremilast, highlighting the potential for SGX945 as an effective maintenance therapy. The company plans to further develop SGX945 to improve patient access through home-based administration.
Read more →SNGXSoligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
Soligenix Inc. is making strides in developing therapies for rare diseases, particularly with its HyBryte treatment for cutaneous T-cell lymphoma, which is nearing the final trial phase. The company is addressing significant unmet medical needs as chronic illnesses among older Americans increase. With supportive government funding, Soligenix is well-positioned to advance its innovative treatments.
Read more →SNGXSoligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
Soligenix Inc. is advancing its treatment HyBryte for cutaneous T-cell lymphoma (CTCL) as part of its efforts to address rare diseases. The company is in the final stages of clinical studies before seeking global marketing approval. This initiative aligns with increasing demands for new therapies in the aging population affected by rare diseases.
Read more →SNGXSoligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. has completed the enrollment of 50 patients for the interim analysis in its Phase 3 clinical trial of HyBryte™ for cutaneous T-cell lymphoma (CTCL). The interim analysis is scheduled for the second quarter of 2026, with an overall blinded study response rate of 48% observed so far. The study aims to confirm the efficacy and safety of HyBryte™, which has shown promising results in earlier trials.
Read more →SNGX▲ +7%on this news
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
Soligenix, Inc. reported its third quarter financial results for 2025, highlighting no revenue and a net loss of $2.5 million. The company is focused on upcoming milestones, including results from its Phase 2a trial for psoriasis and updates on its Phase 3 study for cutaneous T-cell lymphoma. The Data Monitoring Committee confirmed no safety concerns for HyBryte™, and the company has a cash position of approximately $10.5 million.
Read more →SNGX▲ +19.7%on this news· ran to +32% by day 1
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. has announced that its first Data Monitoring Committee meeting for the Phase 3 clinical trial evaluating HyBryte™ for treating cutaneous T-cell lymphoma concluded with no safety concerns. The study shows promise, building on a previous statistically significant trial while aiming to complete patient enrollment by late 2025. Interim efficacy analysis is expected in the first half of 2026, further establishing the treatment's potential in patients with limited options. HyBryte™ continues to be recognized for its benign side effect profile and efficacy in early-stage disease.
Read more →SNGXSoligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Soligenix, Inc. has expanded its European Medical Advisory Board to enhance strategic guidance for its Phase 3 study of HyBryte™ in treating cutaneous T-cell lymphoma (CTCL). The study aims to enroll around 80 patients and report results in late 2026. The involvement of esteemed dermatologists is expected to aid in navigating regulatory processes and improving treatment outcomes.
Read more →SNGXSoligenix Announces Closing of $7.5 Million Public Offering
Soligenix, Inc. has successfully closed a public offering, raising approximately $7.5 million. This funding will extend the company's cash runway through 2026, allowing for continued development of its products aimed at treating rare diseases. The offering included 5,555,560 shares of common stock and warrants, with proceeds designated for research and development activities.
Read more →SNGX▼ -25.9%on this newsshared move
Soligenix Announces Pricing of $7.5 Million Public OfferingUSA - EnglishUSA - English
Soligenix, Inc. has priced a public offering to raise $7.5 million by selling 5,555,560 shares of common stock and warrants. The offering is expected to close on September 29, 2025, subject to customary conditions. Proceeds will be used to fund research, development, and general corporate purposes. The company is focused on treating rare diseases with unmet medical needs.
Read more →SNGX▼ -16.3%on this news· ran to -48% by day 3shared move
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
Soligenix, Inc. has appointed Dr. Tomas J. Philipson as a Strategic Advisor, leveraging his extensive experience in U.S. economic and healthcare policy. Dr. Philipson's role will support the advancement of HyBryte™, currently in a confirmatory Phase 3 clinical trial for cutaneous T-cell lymphoma (CTCL). The company aims to utilize his expertise to navigate regulatory pathways and enhance its rare disease pipeline.
Read more →SNGXSoligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
Soligenix has announced the publication of a study demonstrating the long-term stability of its Ebola vaccines, formulated using the ThermoVax® platform. The vaccines maintained their potency after two years at temperatures up to 40°C. This advancement could enhance vaccination logistics in virus-endemic regions and during pandemics. The study was conducted in collaboration with the University of Hawai'i.
Read more →SNGXSoligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Soligenix, Inc. has announced that its CEO, Dr. Christopher J. Schaber, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The company aims to showcase its advancements in treating rare diseases and will also hold one-on-one meetings with registered attendees. The presentation will be available on-demand starting September 5, 2025.
Read more →SNGX▲ +78.4%on this news
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
Soligenix, Inc. announced that the FDA has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for the treatment of Behçet's Disease. This designation follows positive results from a Phase 2a clinical study demonstrating the drug's efficacy and safety. The designation provides Soligenix with seven years of market exclusivity upon approval and various financial incentives to support further development.
Read more →SNGX▲ +20%on this news· ran to +51% by day 3shared move
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
Soligenix, Inc. recently reported its second-quarter financial results for 2025, highlighting significant progress in its rare disease pipeline, including upcoming clinical trial milestones. The company successfully completed a Phase 2a proof of concept study for SGX945, indicating biological efficacy in treating Behçet's Disease. Despite this progress, Soligenix reported no revenue for the quarter and a net loss of $2.7 million, largely due to rising operating expenses. The firm has approximately $5.1 million in cash as of June 30, 2025, and is exploring various strategic options to advance its pipeline.
Read more →SNGXSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy
Soligenix Inc. is advancing its HyBryte(TM) platform, a novel therapy for cutaneous T-cell lymphoma (CTCL), targeting an unmet need in the aging population. The company has established domestic manufacturing for the active ingredient and is moving towards potential commercialization following a successful Phase 3 study. This initiative aligns with broader efforts to improve access to treatments for rare diseases.
Read more →SNGX▲ +134.4%on this newsshared move
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet
Soligenix, Inc. announced positive results from its Phase 2a clinical trial of SGX945 for Behçet's Disease, achieving its objective of demonstrating biological efficacy. The study showed that SGX945 produced significant improvements similar to those observed in apremilast, particularly in reducing oral ulcers and pain. Seven out of eight patients reported benefits following treatment, which supports further development of SGX945 for this orphan disease. The company plans additional studies to explore the potential of SGX945 as a self-administered treatment for Behçet's Disease.
Read more →SNGX▲ +8.9%on this news
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
Soligenix, Inc. (SNGX) provided a corporate update detailing progress on its late-stage biopharmaceutical pipeline focused on rare diseases. Key highlights include expected top-line results for the Phase 3 FLASH2 trial of HyBryte™ in early-stage cutaneous T-cell lymphoma in late 2026, as well as updates on ongoing studies for psoriasis and Behçet's Disease. The company anticipates substantial commercial opportunities, projecting peak annual net sales from HyBryte™ to exceed $90 million in the U.S. alone, with total market potential across indications estimated at ~$2 billion. Soligenix continues to explore strategic partnerships to enhance its position and capitalize on its product pipeline.
Read more →SNGX▲ +7.6%on this news
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Soligenix, Inc. has announced the successful transfer of its synthetic hypericin manufacturing to the U.S. through its collaboration with Sterling Pharma Solutions. This move is anticipated to enhance the commercialization process for its topical drug products, HyBryte™ and SGX302, aimed at treating cutaneous T-cell lymphoma (CTCL) and psoriasis. HyBryte™ has shown promising results in clinical trials, with significant efficacy compared to placebo in treating CTCL. The company also plans to initiate a confirmatory Phase 3 trial, FLASH2, to further validate HyBryte's effectiveness.
Read more →SNGXSoligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
Soligenix, Inc. highlights Dr. Ellen Kim's insights on HyBryte™, a promising therapy for cutaneous T-cell lymphoma (CTCL). In a recent Q&A, she emphasized the need for safer treatments and reported positive outcomes from ongoing Phase 3 trials. HyBryte™ is noted for its unique non-mutagenic mechanism, potentially reducing risks associated with traditional therapies.
Read more →SNGXSoligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
Soligenix, Inc. reported its financial results and key accomplishments for the quarter ending March 31, 2025. The company has highlighted its focus on advancing clinical programs, particularly the upcoming results for HyBryte™ and SGX945 in various disease indications. Although it ended the period with a cash balance of approximately $7.3 million, the company reported no revenue and an increased net loss, raising concerns about its financial outlook amidst ongoing clinical trials. Positive interim results from a study of HyBryte™ were noted as a significant recent achievement.
Read more →SNGX▼ -9.9%on this news
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
Soligenix has reported interim results from a study showing that 75% of patients with early-stage cutaneous T-cell lymphoma (CTCL) achieved 'Treatment Success' after 18 weeks of treatment with HyBryte™. This open-label study, funded by the FDA, reinforces the rapid response and safety profile of the therapy. The findings are expected to support ongoing recruitment for the confirmatory FLASH2 study, which aims to further evaluate the effectiveness and safety of HyBryte™. The study highlights HyBryte™’s potential as a novel treatment option for patients with limited safe therapies available.
Read more →SNGXSoligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
Soligenix, Inc. announced a publication detailing the efficacy of CiVax™, a thermostabilized subunit vaccine, showing it provides broader protection against COVID-19 variants compared to traditional mRNA vaccines. The study, conducted in collaboration with the University of Hawai'i, highlights that the combination of CiVax™ as a booster along with an adenovirus vaccine leads to robust immune responses in non-human primates. CiVax™'s heat stability allows for easier distribution and storage compared to other vaccine types. This innovation may enhance vaccination efforts globally, particularly in addressing rare diseases and future pandemics.
Read more →SNGXSoligenix Announces Recent Accomplishments and Year End 2024 Financial Results
Soligenix, Inc. announced its financial results for 2024, highlighting a focus on advancing its clinical programs. The company reported a significant decrease in revenue and an increase in net loss, attributing these changes to timing of government funding and research costs. Despite these challenges, Soligenix provided positive updates on ongoing clinical trials and maintains a cash position that should support its operations through 2025. The company is exploring strategic options for advancing its pipeline, including partnerships and financing opportunities.
Read more →SNGXHyBryte™ Treatment Studies Presented at Two Medical Conferences in March
Soligenix, Inc. announced that lead investigators will present findings on HyBryte™ and SGX302 at two major medical conferences. The results demonstrate promising efficacy of HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) and psoriasis compared to current therapies. The presentations are part of an ongoing investigation showing the long-term safety and tolerability of HyBryte™, which has received special designations from regulatory authorities for its innovative treatment approach. These conferences are significant for disseminating pivotal research supporting the advancements in treatment options for rare diseases.
Read more →SNGXSoligenix to Present at BIO CEO & Investor Conference
Soligenix, Inc. has announced its participation in the BIO CEO & Investor Conference set for February 10-11, 2025, in New York City. This event will provide an opportunity for the company to present its late-stage biopharmaceutical developments, particularly for rare diseases. Notably, following a successful first Phase 3 trial for its product HyBryte™ (SGX301), the company is seeking regulatory approvals for potential commercialization worldwide. However, there remain significant uncertainties surrounding the outcomes of its ongoing clinical trials and funding prospects.
Read more →SNGXSoligenix to Present at Upcoming Investor Conferences
Soligenix, Inc. will present at two upcoming investor conferences: the Sequire Investor Summit and The Microcap Conference, where management will also engage in one-on-one meetings with attendees. The company is focused on developing treatments for rare diseases, including potential therapies for cutaneous T-cell lymphoma and psoriasis. However, they face challenges such as uncertainty in clinical trial outcomes and the need for regulatory approvals. Financial dependence on grants and government contracts further adds to their risks in sustaining development efforts.
Read more →SNGX▼ -16%on this news· ran to -27% by day 1shared move
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Soligenix, Inc. has reported positive interim results from an investigator-initiated study of its product HyBryte™ for early-stage cutaneous T-cell lymphoma. The study has shown that over 70% of the treated patients have achieved significant improvement after 18 weeks. HyBryte™, which utilizes synthetic hypericin, has been noted for its safety and effectiveness compared to traditional therapies. The ongoing support from the FDA adds confidence to the program as further results are anticipated.
Read more →SNGXSoligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. has initiated patient enrollment for its confirmatory Phase 3 clinical trial named FLASH2, focusing on the treatment of cutaneous T-cell lymphoma (CTCL) using HyBryte™. This study builds upon previous successful trials demonstrating HyBryte™'s efficacy and safety. The FLASH2 trial will evaluate approximately 80 patients over 18 weeks of treatment, aiming to confirm the benefits noted in earlier studies. Soligenix anticipates interim results in early 2026 and has engaged extensively with patient advocacy groups for this trial.
Read more →SNGXHyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
Soligenix, Inc. announced positive results from its HPN-CTCL-04 study of HyBryte™ (synthetic hypericin) for treating plaque lesions in CTCL patients. Following a 12-week treatment period, patients treated with HyBryte™ showed a 60% treatment response rate, improving further during a subsequent 4-week follow-up. In contrast, the Valchlor® group had a significantly lower response rate, with no patients achieving substantial improvements. HyBryte™ demonstrated not only efficacy but also a favorable safety profile.
Read more →SNGXSoligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Soligenix, Inc. has announced the formation of a European Medical Advisory Board to guide its Phase 3 clinical study of HyBryte™ for cutaneous T-cell lymphoma (CTCL). This advisory group will include leading CTCL experts and enhance the study's strategic framework, which aims to enroll around 80 patients in the U.S. and Europe by the end of 2024. The study follows positive feedback from the European Medicines Agency regarding its design, and top-line results are expected by 2026.
Read more →SNGXSoligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet
Soligenix, Inc. has announced the opening of patient enrollment for its Phase 2 clinical trial evaluating SGX945 (dusquetide) for Behçet's Disease. The trial will enroll approximately 25 patients suffering from mild to moderate symptoms and aims to assess the efficacy of dusquetide in treating painful ulcers. This study follows previous positive experiences with the drug in oral mucositis and highlights the significant unmet medical need for Behçet's Disease, affecting up to 1 million people globally. Results from this trial are expected in the first half of 2025.
Read more →SNGXSoligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results
Soligenix, Inc. reported its third-quarter financial results and highlighted recent achievements, including patent grants for synthetic hypericin. The company is preparing to initiate a Phase 3 study for its treatment of early-stage cutaneous T-cell lymphoma and a Phase 2 study for Behçet's disease. Financially, Soligenix reported no revenue for the quarter, maintaining a net loss of $1.7 million. The company has approximately $9.8 million in cash to support ongoing projects and enhance shareholder value through strategic partnerships.
Read more →SNGXSoligenix, Inc. to Present at the 2024 ThinkEquity Conference
Soligenix, Inc. will participate in the ThinkEquity Conference on October 30, 2024, in New York. CFO Jonathan Guarino will present at 9:00 AM ET, with management available for one-on-one investor meetings. The company focuses on developing treatments for rare diseases, including ongoing clinical trials for HyBryte™ and other therapeutic candidates.
Read more →SNGXSoligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Soligenix, Inc. received a Hong Kong patent for its innovative method of producing synthetic hypericin, a key ingredient in its treatments for cutaneous T-cell lymphoma and psoriasis. This patent secures intellectual property rights similar to existing patents in the U.S. and Europe, expiring in 2036. HyBryte™, which utilizes synthetic hypericin, has shown statistically significant efficacy in earlier clinical trials and is set for a confirmatory Phase 3 study by the end of 2024. The company aims to meet the significant medical needs associated with these diseases through its ongoing clinical developments.
Read more →SNGXSoligenix Invited to Present at Upcoming Investor Conferences
Soligenix, Inc. has announced its participation in several upcoming investor conferences where it will provide corporate updates. These include the Maxim Healthcare Virtual Summit, ThinkEquity Conference, and Spartan Capital Investor Conference. The company, noted for its focus on rare disease treatment, is moving towards commercialization of its products like HyBryte™. However, it faces uncertainties regarding the success of its clinical trials and the regulatory approval process.
Read more →SNGX▲ +9.3%on this news
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
Soligenix, Inc. announced that findings from supportive trials of its HyBryte™ therapy for cutaneous T-cell lymphoma (CTCL) will be presented at the EORTC Annual Meeting. The presentations will highlight the effectiveness of longer treatment times and increased light doses, with results indicating a significant improvement in response rates when compared to previous treatments. This potentially positions HyBryte™ as a safer alternative treatment in this therapeutic area. A second Phase 3 study, FLASH2, is anticipated to begin by the end of 2024 to further evaluate its efficacy.
Read more →SNGX▼ -18.9%on this newsshared move
Soligenix Announces Partnership with Sterling Pharma Solutions
Soligenix, Inc. has announced a partnership with Sterling Pharma Solutions to enhance the manufacturing of synthetic hypericin, the active ingredient in its topical treatments for cutaneous T-cell lymphoma (CTCL) and psoriasis. This collaboration aims to optimize scalability and develop a commercial manufacturing process in support of ongoing clinical trials, particularly for the HyBryte™ treatment. The FDA has granted orphan drug and fast track designations to HyBryte™, which shows promising efficacy and safety in treating CTCL. A second confirmatory Phase 3 trial, FLASH2, is set to begin before the end of 2024 to further validate the treatment's effectiveness.
Read more →SNGXJoin Soligenix
Soligenix, Inc. is hosting a webinar on September 18, 2024, to discuss its development pipeline and upcoming milestones. The company is advancing its photodynamic therapy product HyBryte™ for cutaneous T-cell lymphoma and is also pursuing treatments for psoriasis and Behçet's Disease. With potential sales in the billions, Soligenix’s pipeline is buoyed by governmental support for its vaccine technologies. However, the company faces uncertainties regarding the success of its clinical trials and securing regulatory approvals.
Read more →SNGX▲ +8.9%on this news
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
Soligenix, Inc. announced the grant of a European patent for a novel method of producing synthetic hypericin, a key ingredient in its CTCL treatment, HyBryte. This patent strengthens the company’s intellectual property portfolio as it proceeds towards launching a confirmatory Phase 3 clinical trial for HyBryte, which has already demonstrated efficacy in previous trials. The new patent and ongoing development underscore the potential for HyBryte to address unmet medical needs within the treatment landscape of cutaneous T-cell lymphoma.
Read more →SNGXSoligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results
Soligenix, Inc. announced its financial results for the second quarter of 2024, revealing a net loss of $1.6 million. The company cited recent accomplishments, including positive clinical results from HyBryte in treating cutaneous T-cell lymphoma and plans for a Phase 2 study in Behçet’s disease. Additionally, Soligenix has regained compliance with Nasdaq regulations after a period of concern regarding its stock price. Despite the encouraging clinical data, the company reported a decrease in revenues from government contracts compared to the same period last year.
Read more →SNGX▲ +271%on this news· ran to +287% by day 1
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Soligenix, Inc. has announced positive interim results from their investigator-initiated study of HyBryte™ for early-stage cutaneous T-cell lymphoma (CTCL). Three out of four patients who completed the 12-week therapy achieved predefined 'Treatment Success' with significant improvements in their condition. The study received support from a $2.6 million FDA grant, and no adverse events were reported, underscoring the treatment's safety. The company looks forward to further evaluating HyBryte™ in upcoming phases of the trial.
Read more →SNGX▼ -21.6%on this news
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix announced positive results from a comparative study of its drug HyBryte™ against Valchlor® in treating cutaneous T-cell lymphoma. The study indicated that 60% of patients treated with HyBryte™ showed a 50% improvement in a key measure compared to only 20% with Valchlor®. Despite a small sample size, the results suggest HyBryte™ has a rapid and effective response and a better safety profile. The results build on prior studies and set the stage for a forthcoming Phase 3 replication study.
Read more →SNGXA Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
Soligenix, Inc. will present its innovative subunit vaccine technologies for filoviruses, specifically SuVax™ and MarVax™, at the ASM Microbe Conference in June 2024. These vaccines have shown complete protection in non-human primate studies and have received Orphan Drug Designation from the FDA. The presentation will include a comparison with mRNA and viral vectored vaccine technologies, addressing their respective advantages and disadvantages. The company aims to leverage its advancements in thermostabilized vaccines to meet urgent public health needs.
Read more →SNGX▼ -10%on this news
Soligenix Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on
Soligenix, Inc. has announced a reverse stock split at a ratio of 1-for-16, effective June 5, 2024. This decision follows approval from stockholders during the 2024 Annual Meeting. The stock will continue trading under the ticker SNGX on a split-adjusted basis starting June 6, 2024. The reverse split aims to increase the share price and attract more investors while maintaining stockholder interests with automatic adjustments for shares held.
Read more →SNGX▼ -10%on this news
Soligenix Announces Reverse Stock Split
Soligenix, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-16, effective from June 5, 2024. The decision was approved by stockholders during the 2024 Annual Meeting, allowing the Board of Directors discretion in the split. Following the split, the number of outstanding shares will decrease significantly from over 15 million to approximately 987,490. This move is seen as a strategy to enhance the stock's trading value on the Nasdaq Capital Market.
Read more →SNGXSoligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
Soligenix, Inc. is urging its shareholders to vote their shares prior to the reconvened annual meeting on May 30, 2024. The company emphasizes that all eligible stockholders, including those who have sold shares since the record date, are encouraged to participate. Alongside this call to action, Soligenix is advancing its product candidates aimed at rare diseases, though the path to regulatory approval remains uncertain and subject to various challenges.
Read more →SNGXSoligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Soligenix, Inc. announced the adjournment of its 2024 Annual Meeting of Stockholders due to insufficient voting power, with only 48% of shares represented. The meeting will reconvene on May 30, 2024, allowing stockholders more time to vote. The company is focused on developing treatments for rare diseases and is encouraging stockholder participation to ensure necessary quorum is achieved for decision-making.
Read more →SNGXSuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
Soligenix, Inc. (SNGX) announced that Professor Axel Lehrer will present data on their thermostable vaccine platform for Sudan ebolavirus (SuVax™) and Marburg marburgvirus (MarVax™) at the Vaccine Technology IX Conference in Mexico. These vaccine candidates have shown complete protection in non-human primate studies and leverage innovative thermostabilization techniques. Soligenix has received Orphan Drug Designation for both vaccines, enhancing their potential market position and access to regulatory benefits. The presentation is set for May 22, 2024, showcasing advancements in vaccine technology.
Read more →SNGXSoligenix Encourages Stockholders to Vote Prior to Annual Meeting
Soligenix, Inc. has called on its stockholders to participate in the upcoming virtual Annual Meeting on May 23, 2024. The company emphasizes the importance of this meeting for voting on crucial proposals to further develop its rare disease pipeline, including the HyBryte™ treatment for cutaneous T-cell lymphoma. Stockholders eligible as of April 10, 2024, are encouraged to vote early through various methods. The meeting's outcomes are significant as they will impact the direction and funding of the company's development programs, which include multiple therapeutic candidates.
Read more →SNGX▲ +7.3%on this newsshared move
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
Soligenix, Inc. announced that a compatibility study evaluating HyBryte™ for cutaneous T-cell lymphoma (CTCL) has shown promising clinical results, confirming findings from the Phase 3 FLASH study. The open-label study involved nine patients who received eight weeks of treatment, with a 22% response rate noted. Additionally, significant safety findings were reported, highlighting minimal systemic exposure to the active compound. The positive outcomes suggest a strong potential for HyBryte™ as a safe and effective therapy for CTCL.
Read more →SNGXSoligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
Soligenix, Inc. announced its recent accomplishments and financial results for the first quarter of 2024, including a public offering that raised approximately $4.75 million. The European Medicines Agency approved the study design for a Phase 3 trial of HyBryte™ for treating early-stage cutaneous T-cell lymphoma. The company also received orphan drug designations from the FDA for its products aimed at treating infectious diseases. Financially, Soligenix reported a decrease in revenue and an increase in net loss, highlighting the challenges it faces despite recent achievements in drug development.
Read more →SNGXSoligenix to Present at Upcoming Conferences
Soligenix, Inc. announced that it will present at several upcoming conferences, including the Aegis Virtual Conference and BioNJ's 14th Annual BioPartnering Conference. The company is focused on developing treatments for rare diseases and has promising results from its Phase 3 clinical trials for HyBryte™ in treating cutaneous T-cell lymphoma. However, the company faces uncertainties regarding the success of further trials and obtaining necessary regulatory approvals, compounded by reliance on government funding.
Read more →SNGX▲ +11.5%on this news
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
Soligenix, Inc. has received notice of intent to grant additional patents for its filovirus vaccine platform in the United Kingdom and South Africa. This extends their patent protection for vaccines targeting lethal viruses such as Ebola and Marburg, which have shown complete protection in non-human primates. The unique formulation allows for thermostabilization, enabling storage at higher temperatures, which is crucial for deployment in areas with unreliable power supplies. These advancements can significantly enhance global public health responses to viral outbreaks.
Read more →SNGX▼ -14.6%on this news
Soligenix Announces Pricing of $4.75 Million Public Offering
Soligenix, Inc. announced the pricing of a public offering to sell approximately 11,875,000 shares of common stock and similar warrants at a price of $0.40 per share. This offering is expected to generate about $4.75 million in gross proceeds, which will be utilized for research and development, along with other corporate expenses. The transaction's expected closing date is around April 22, 2024, pending standard closing conditions. Soligenix is focused on developing therapies for rare diseases and aims to support the commercialization of its treatments, including HyBryte for cutaneous T-cell lymphoma.
Read more →SNGX▲ +21.7%on this newsshared move
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Soligenix, Inc. has received orphan drug designation from the FDA for its MarVax™ vaccine, aimed at preventing and providing post-exposure prophylaxis against Marburg marburgvirus infection. This designation grants the company seven years of market exclusivity upon FDA approval and offers various regulatory benefits. The heat stable subunit vaccine has shown promising results, with significant protection in animal trials. This development highlights the company's ongoing commitment to addressing rare diseases with unmet medical needs.
Read more →SNGX▼ -10.1%on this news
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Soligenix, Inc. has received agreement from the European Medicines Agency on the design of a second confirmatory Phase 3 placebo-controlled trial for its drug, HyBryte™, to treat early-stage cutaneous T-cell lymphoma (CTCL). This trial aims to replicate and potentially improve on positive results from a previous study, assessing treatment safety and efficacy over an 18-week continuous period with approximately 80 patients. The company anticipates patient enrollment to begin by the end of 2024, with top-line results expected in the second half of 2026.
Read more →SNGXSoligenix Announces Recent Accomplishments and Year End 2023 Financial Results
Soligenix, Inc. has announced its financial results for the year ending December 31, 2023, reporting a decrease in revenue and maintaining substantial net losses despite some positive advancements in its clinical pipeline. The company is focusing on collaborations with regulatory bodies, with progress noted for its drug candidates SGX302 and SGX945, which have received positive attention from the FDA. Additionally, a new bivalent vaccine has demonstrated promising preclinical efficacy. Soligenix aims to manage resources carefully while exploring strategic partnerships moving forward.
Read more →SNGX▲ +5.5%on this news
Soligenix Announces Formation of Behçet
Soligenix, Inc. announced the formation of a Medical Advisory Board (MAB) to provide guidance for the clinical development of SGX945, a treatment for Behçet's Disease. The FDA has granted Fast Track designation for SGX945, which is set to enter a Phase 2a clinical study in 2024. The MAB is composed of leading experts in Behçet's Disease, who will assist with clinical strategies and regulatory interactions. This initiative aims to enhance the treatment landscape for patients suffering from this chronic condition.
Read more →SNGXSoligenix to Present at The Microcap Conference
Soligenix, Inc. will present at The Microcap Conference scheduled for January 30 to February 1, 2024, at Caesars Atlantic City Hotel & Casino. The company focuses on developing products for rare diseases, including HyBryte™ (SGX301), which has completed a successful Phase 3 study and is seeking regulatory approval. Attendees will have the opportunity for one-on-one meetings with Soligenix management to discuss the company's initiatives and products.
Read more →SNGX▲ +12.3%on this newsshared move
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
Soligenix, Inc. announced the publication of a preclinical study demonstrating that its novel bivalent vaccine provides complete protection against both Sudan ebolavirus and Marburg marburgvirus. This significant advance, published in the journal Vaccine, shows the vaccine's ability to remain stable under high temperatures for over two years, addressing the logistical challenges faced in virus outbreak responses. The ongoing development of this vaccine platform, supported by NIH grants, aims to enhance public health responses to filovirus outbreaks in endemic regions.
Read more →SNGX▼ -25.5%on this news
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
Soligenix, Inc. announced the publication of findings regarding HyBryte™ in the treatment of cutaneous T-cell lymphoma (CTCL) in Frontiers in Drug Discovery. The review highlights HyBryte™'s ability to meet the unmet medical needs of early-stage CTCL patients by offering a treatment that demonstrates strong efficacy and an excellent safety profile. The published Phase 3 FLASH trial results indicate significant improvement in patient outcomes, reinforcing the viability of HyBryte™ as a promising first-line therapeutic option for CTCL. Additionally, the treatment's mechanism of action avoids risks commonly associated with current therapies.
Read more →SNGX▲ +136%on this newsshared move
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet
Soligenix, Inc. announced that the FDA has approved its IND application for SGX945 (dusquetide) to conduct a Phase 2a clinical trial for treating aphthous ulcers in Behçet's disease. The trial aims to assess the drug's safety and efficacy, with patient enrollment expected to begin in late 2024. Dusquetide is a novel innate defense regulator previously shown to be effective in oral mucositis treatment. The need for effective therapies in Behçet's disease, which currently has limited treatment options, underscores the potential significance of dusquetide for patients.
Read more →SNGXSoligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
Soligenix, Inc. reported its third-quarter financial results for 2023, highlighting a continued focus on the development of therapies for rare diseases. The company is in discussions with the FDA regarding a Phase 3 study for HyBryte™ in the treatment of cutaneous T-cell lymphoma and is actively enrolling patients in a Phase 2a trial for SGX302 for psoriasis. Financially, while revenues decreased, the company reported a reduced net loss year-over-year and emphasized careful cash management as it seeks strategic options for future growth.
Read more →SNGXSoligenix to Present at The ThinkEquity Conference
Soligenix, Inc. announced it will present at the ThinkEquity Conference on October 19, 2023. The late-stage biopharmaceutical company is focused on developing treatments for rare diseases and has plans for one-on-one meetings between attendees and key management members. Soligenix is advancing its product candidates, including HyBryte™, which has completed a Phase 3 trial for cutaneous T-cell lymphoma. This presentation could enhance visibility and support fundraising efforts.
Read more →SNGXSoligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
Soligenix announced that its thermostabilized bivalent and trivalent filovirus vaccines have achieved two years of stability at 40 degrees Celsius. This milestone indicates that the vaccines remain effective without requiring cold chain storage, offering a robust solution for delivering these potentially life-saving vaccines in areas with unreliable power supply. The vaccines have already shown 100% protection in non-human primates against lethal Ebola and Marburg virus challenges. This development is part of ongoing collaborations aimed at enhancing global health preparedness against filoviruses.
Read more →SNGX▲ +5.6%on this newsshared move
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
Soligenix, Inc. announced the adjournment of its 2023 Annual Meeting of Stockholders to October 18, 2023, due to insufficient voter representation. This postponement aims to allow additional time for stockholders to vote on existing and new proposals. Included in the new proposals is the ratification of Cherry Bekaert LLP as the independent registered public accounting firm. Stockholders are encouraged to participate in the voting process to ensure proper governance.
Read more →SNGXSoligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
Soligenix, Inc. reported on its recent accomplishments and financial results for Q2 2023, highlighting progress in clinical trials and regulatory discussions with the FDA. The company received a $2.6 million grant to support an expanded treatment trial for its HyBryte™ product aimed at treating cutaneous T-cell lymphoma. In addition, Soligenix reported a decrease in net loss compared to the previous year, attributed to lower operating expenses. However, uncertainties remain regarding future regulatory approvals and commercialization of their therapies.
Read more →SNGXHyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
Soligenix, Inc. has announced the opening of patient enrollment for an investigator-initiated study at the University of Pennsylvania to evaluate the expanded use of HyBryte™ in early-stage cutaneous T-cell lymphoma (CTCL). This study, which is supported by a $2.6 million FDA grant, aims to provide an alternative treatment option for patients with limited available therapies. The trial follows the positive results from the previously published Phase 3 FLASH study, showing efficacy and a favorable safety profile. The open-label nature of the trial will allow for treatment over a period of up to 12 months.
Read more →SNGXSoligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis
Soligenix, Inc. has announced the expansion of its Phase 2a trial for SGX302 (synthetic hypericin) aimed at treating mild-to-moderate psoriasis following positive initial results. The initial cohort of five subjects exhibited notable improvements in the psoriasis area and severity index (PASI). The trial's expansion will include additional patients to further evaluate SGX302's efficacy in standard care settings. This move is part of the company's broader strategy to explore synthetic hypericin's applications, given the significant unmet medical needs in psoriasis treatment.
Read more →SNGX▼ -6%on this news
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis
Soligenix, Inc. has received a patent from the European Patent Office for the therapeutic use of dusquetide, a peptide intended for treating oral mucositis. This patent complements existing protections in several other countries and underscores the company's commitment to addressing unmet medical needs in rare diseases. Dusquetide, which has shown promising efficacy in earlier clinical trials, also holds Fast Track Designation from the FDA for its application in head and neck cancer patients. The granted therapeutic claims, valid until 2034, provide significant protection for the product's commercialization efforts.
Read more →SNGX▲ +6.8%on this newsshared move
Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
Soligenix, Inc. announced its financial results for Q1 2023, indicating a net loss of $1.0 million, which reflects better management of operating expenses compared to the previous year. The organization achieved positive clinical results from a compatibility study on HyBryte™ and secured funding from a public offering of $8.5 million to continue its rare disease pipeline. Additionally, the FDA approved a Type A Meeting for a second Phase 3 study of HyBryte™ in early-stage CTCL, while the company is evaluating new treatments for Behçet's Disease and has strengthened its leadership team with a new board member experienced in orphan drug development.
Read more →SNGX▼ -5.7%on this newsshared move
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. has announced that the U.S. FDA has granted a Type A meeting to evaluate the protocol for a second Phase 3 study of HyBryte™ in treating cutaneous T-cell lymphoma (CTCL). The upcoming meeting will allow Soligenix to discuss feedback received from the FDA and refine their study design based on previous statistically significant results from an earlier trial. HyBryte™, which utilizes photodynamic therapy, has shown promise in improving patient outcomes while minimizing safety risks associated with other treatments.
Read more →SNGX▼ -12.6%on this news· ran to -25% by day 3shared move
Soligenix Announces Closing of $8.5 Million Public Offering
Soligenix, Inc. has completed an $8.5 million public offering involving the sale of 6,538,500 shares of common stock and related warrants. The offering, priced at $1.30 per share, aims to bolster the company's funding for developing treatments for rare diseases. With the completed funding, Soligenix is proceeding with its regulatory approval processes and advancing commercialization efforts for its products, including HyBryte™ for cutaneous T-cell lymphoma. However, the company faces risks including uncertainties in regulatory approvals and dependence on future funding.
Read more →SNGX▼ -51.8%on this news· ran to -64% by day 3shared move
Soligenix Announces Pricing of $8.5 Million Public Offering
Soligenix, Inc. has announced the pricing of its public offering, which consists of 6,538,500 shares of common stock and accompanying warrants, expected to generate approximately $8.5 million. The offering price is set at $1.30 per share, with immediate warrants exercisable at $1.50 each. The proceeds will be directed towards research, development, and general corporate needs. The closing of the offering is anticipated around May 9, 2023, pending standard conditions.
Read more →SNGX▲ +60.6%on this newsshared move
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. announced positive results from a clinical compatibility study of HyBryte™ for treating cutaneous T-cell lymphoma (CTCL). The study, using a specific light device, confirmed efficacy similar to previous Phase 3 FLASH trial results. All enrolled patients showed improvements in their CAILS scores, reinforcing the drug’s potential. Notably, HyBryte™ exhibits a strong safety profile with minimal systemic absorption.
Read more →SNGX▼ -11.3%on this news· ran to +42% by day 1shared move
Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors
Soligenix, Inc. has appointed Timothy R. Coté, M.D., to its Board of Directors. Dr. Coté brings extensive regulatory and orphan drug development experience from his previous roles at the FDA and NIH. His expertise is expected to assist Soligenix in advancing its rare disease programs, particularly HyBryte™, which has shown promising results in clinical trials for cutaneous T-cell lymphoma. The company looks to leverage Dr. Coté's insights to enhance its product pipeline and regulatory strategies.
Read more →SNGX▲ +9.7%on this news· ran to +48% by day 3shared move
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet
Soligenix, Inc. has entered into an exclusive option agreement with Silk Road Therapeutics to acquire a novel topical formulation of Pentoxifylline for treating Behçet's Disease. This agreement emphasizes the company's focus on addressing significant unmet medical needs in orphan diseases. The formulation has shown promising results in a Phase 2 proof-of-concept study, demonstrating enhanced healing of oral ulcers compared to standard care. The next steps involve further discussions with the FDA regarding trial design for Phase 2/3 development.
Read more →SNGXSoligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix has submitted a Type A Meeting Request to the U.S. FDA to discuss the design of a second Phase 3 study for HyBryte™ in treating early-stage cutaneous T-cell lymphoma (CTCL). This meeting reflects the FDA's recognition of the need for additional therapies and its willingness to provide feedback on clinical study designs. Previous trials have shown statistically significant results for HyBryte™, which uses safe photodynamic therapy, making it a promising treatment alternative for this rare cancer. The company aims for an executable and effective study protocol following FDA guidelines.
Read more →SNGXSoligenix Provides Regulatory Update on HyBryte™
Soligenix, Inc. has announced a regulatory update regarding its drug HyBryte™ aimed at treating early-stage cutaneous T-cell lymphoma (CTCL). Following a Type A Meeting with the FDA, the company is required to conduct a second clinical study to support the NDA due to an RTF letter issued by the FDA. Despite the setback, Soligenix plans to engage collaboratively with the FDA to define the protocol for the necessary trial. The Phase 3 FLASH study had previously shown promising results, positioning HyBryte™ as a potentially safer therapy for patients with CTCL.
Read more →SNGXSoligenix Provides Regulatory Update on HyBryte Princeton, NJ
Soligenix, Inc. recently held a Type A Meeting with the FDA regarding its new drug application (NDA) for HyBryte, designed to treat early stage cutaneous T-cell lymphoma (CTCL). The FDA's refusal to file the NDA necessitates the completion of a second clinical study, although they have expressed willingness to discuss protocol designs for this study. Despite the setback, Soligenix continues to engage with the FDA, having demonstrated positive results in their previously conducted Phase 3 FLASH study. The company remains focused on bringing this promising treatment option to market for patients suffering from CTCL.
Read more →SNGXSoligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302
Soligenix, Inc. announced the approval of 'hypericin sodium' as the nonproprietary name for its novel active ingredient used in HyBryte™ and SGX302, which target cutaneous T-cell lymphoma and psoriasis, respectively. With promising efficacy data from recent clinical trials, the company looks forward to advancing the substance's classification with WHO. However, the HyBryte™ new drug application faces challenges after receiving a Refusal to File letter from the FDA, prompting a scheduled meeting to address compliance issues. The development of SGX302 continues with a Phase 2a clinical trial currently underway.
Read more →SNGXSoligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. announced that the FDA granted a Type A meeting to discuss the refusal to file letter related to their NDA for HyBryte™, a treatment for early-stage cutaneous T-cell lymphoma (CTCL). The meeting aims to address concerns raised by the FDA and provide clarity on the path forward. HyBryte™, which utilizes synthetic hypericin and photodynamic therapy, demonstrated significant efficacy in a recent Phase 3 study, highlighting its safety and potential benefits over existing treatments for CTCL.
Read more →SNGXSoligenix Announces Recent Accomplishments And Year-End 2022 Financial Results
Soligenix, Inc. reported its financial results for the year ending December 31, 2022, highlighting several key accomplishments and challenges. The company experienced a net loss of $13.8 million, attributed to increased legal expenses and minimal revenue growth. Despite receiving a refusal to file letter from the FDA regarding its NDA for HyBryte™, Soligenix has scheduled a Type A meeting with the agency to clarify the issues raised. The company is also expanding synthetic hypericin's application into psoriasis and has retained a cash position of approximately $13.4 million to support its initiatives.
Read more →SNGX▲ +6.6%on this news
Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. has submitted a Type A Meeting Request to the FDA to discuss a refusal to file letter concerning their new drug application for HyBryte™, a treatment for early stage cutaneous T-cell lymphoma (CTCL). The meeting is expected to occur within 30 days of the FDA's receipt of the request. HyBryte™ has shown promising results in Phase 3 trials, demonstrating significant effectiveness while avoiding the significant risks associated with conventional treatments. This development reflects the company's commitment to advancing HyBryte™ through the regulatory process following its successful clinical outcomes.
Read more →SNGX▼ -18.1%on this news
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. announced that the U.S. FDA issued a Refusal to File letter for its new drug application for HyBryte™, a treatment for cutaneous T-cell lymphoma (CTCL). The FDA deemed the submission incomplete, requiring further information before it could be considered for approval. Soligenix plans to meet with the FDA to address the identified issues and clarify the requirements for resubmission. Meanwhile, results from clinical trials have shown significant improvements in treatment outcomes, though this setback poses challenges for the company.
Read more →SNGXSoligenix Invited to Present at the Virtual Investor Summit Event
Soligenix, Inc. announced that it will present at the Virtual Investor Summit on January 26, 2023. The company was selected as one of 25 micro-cap companies due to its significant catalysts, including the submission of a new drug application for its lead candidate, HyBryte™, for cutaneous T-cell lymphoma. Soligenix's management will also hold one-on-one meetings with investors during the conference, emphasizing its ongoing efforts to address rare diseases with unmet medical needs. The firm has a portfolio that includes various therapies and vaccines under development.
Read more →SNGXSoligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
PRINCETON, N.J., Dec. 23, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge
RiVax®-Vaccinated NHP survival was statistically significantly correlated with an epitope-specific serum assay ("EPICC") prior to challenge Correlates of protection are essential to support approval via the FDA "Animal Rule" PRINCETON, N.J., Dec. 20, 2022 /PRNewswire/ -- Solige
Read more →SNGXSoligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540
Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis Study HPN-PSR-01 opens patient enrollment PRINCETON, NJ - December 19, 2022 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bioph
Read more →SNGXSoligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis
Study HPN-PSR-01 opens patient enrollment PRINCETON, N.J., Dec. 19, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an
Read more →SNGX▲ +13.5%on this news· ran to +24% by day 3shared move
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J., Dec. 15, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGX▼ -6.8%on this news
Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., Nov. 15, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results
PRINCETON, N.J., Nov. 10, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rec
Read more →SNGXSoligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
Emerging infectious diseases where no protective vaccines are currently available SuVax™ targets Sudan ebolavirus, origin of a current disease outbreak in Uganda PRINCETON, N.J. , Oct. 27, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-st
Read more →SNGXSoligenix Announces Formation of Psoriasis Medical Advisory Board
Phase 2a clinical study in mild-to-moderate psoriasis initiating in December 2022 PRINCETON, N.J., Oct. 25, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products t
Read more →SNGXSoligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting
Meeting adjourned to November 17, 2022, at 9:00 a.m., Eastern Time Soligenix encourages all stockholders as of record July 25, 2022, who have not yet voted, to vote by 11:59 p.m., Eastern Time on November 16, 2022 PRINCETON, N.J., Oct. 20, 2022 /PRNewswire/ -- Soligenix, Inc. (
Read more →SNGX▼ -5.8%on this news
Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
- Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time - Soligenix encourages all stockholders of record at the close of business on July 25, 2022 who have not yet voted, to vote by 11:59 p.m., Eastern Time on October 18, 2022 PRINCETON, N.J., Sept. 23, 2022 /PRNew
Read more →SNGXSoligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PRINCETON, N.J., Sept. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXU.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Grant supports study of expanded HyBryte™ treatment, including in the Home Use Setting PRINCETON, N.J., Sept. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ
Read more →SNGXSoligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results
PRINCETON, N.J., Aug. 12, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rec
Read more →SNGXSoligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., July 27, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGX▲ +8.8%on this newsshared move
Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen
SERB Pharmaceuticals pursuing therapeutic treatment against ricin poisoning using Soligenix ricin antigen PRINCETON, N.J., July 25, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and co
Read more →SNGX▲ +11.1%on this newsshared move
HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology
Published findings demonstrate that HyBryte™ treatment statistically significantly reduced CTCL lesion size HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL PRINCETON, N.J., July 20, 2022 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix
Read more →SNGXSoligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
Enrollment on Track to Begin in 4th Quarter of 2022 PRINCETON, N.J., June 28, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where th
Read more →SNGXSoligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
Bivalent vaccine provides 100% protection in non-human primates against both Sudan ebolavirus and Marburg marburgvirus Only subunit (protein) vaccine platform shown to protect against potentially lethal Ebola and Marburg viruses PRINCETON, N.J., June 23, 2022 /PRNewswire/ -- So
Read more →SNGX▼ -6.3%on this news
Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified
Paper published in the Journal Structure PRINCETON, N.J., June 1, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an un
Read more →SNGX▲ +10.4%on this news
Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform
Includes thermostabilized Ebola vaccines Includes nanoemulsion adjuvant compatible with lyophilization PRINCETON, N.J. , May 23, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and comm
Read more →SNGXSoligenix to Present at the H.C. Wainwright Global Investment Conference
PRINCETON, N.J., May 18, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the
Read more →SNGX▼ -6.7%on this newsshared move
Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results
PRINCETON, N.J., May 13, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rece
Read more →SNGXSoligenix Receives $1.4M in Non-Dilutive Government Funding
PRINCETON, N.J., April 19, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXSoligenix Announces Recent Accomplishments And Year-End 2021 Financial Results
PRINCETON, N.J., March 29, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its re
Read more →SNGXSoligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron
CiVax™ booster vaccine administered seven months after primary vaccination with COVID-19 adenovirus vaccine shows rapid enhancement of neutralizing antibody responses in non-human primates Neutralizing antibodies against Delta and original strain increased by up to 27-fold withi
Read more →SNGXSoligenix to Present at the Q1 Virtual Investor Summit
PRINCETON, N.J., March 2, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix to Present at the 2022 BIO CEO & Investor Conference
PRINCETON, N.J., Feb. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its
Read more →SNGXSoligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts
PRINCETON, N.J., Jan. 10, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update
Read more →SNGX▲ +5.9%on this newsshared move
Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
PRINCETON, N.J., Jan. 4, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that dus
Read more →SNGXSoligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results
PRINCETON, N.J., Nov. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rec
Read more →SNGXSoligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom
PRINCETON, N.J., Nov. 8, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine
PRINCETON, N.J., Nov. 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publicat
Read more →SNGXThermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and Development
PRINCETON, N.J., Nov. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ore
Read more →SNGXHyBryte™ FLASH Study Selected as a
PRINCETON, N.J., Oct. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today their p
Read more →SNGXSoligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
PRINCETON, N.J., Sept. 28, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today public
Read more →SNGXSoligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference
PRINCETON, N.J., Sept. 27, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXSoligenix to Advance Synthetic Hypericin Development in Psoriasis
PRINCETON, N.J., Sept. 16, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that f
Read more →SNGXFDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
PRINCETON, N.J., Sept. 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases
PRINCETON, N.J., Aug. 23, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publi
Read more →SNGXSoligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
PRINCETON, N.J., Aug. 18, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positiv
Read more →SNGXSoligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results
PRINCETON, N.J., Aug. 13, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rec
Read more →SNGXHyBryte™ Positive Pivotal Phase 3 FLASH Study Selected for Presentation at the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting
PRINCETON, N.J., June 22, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that El
Read more →SNGXSoligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency
PRINCETON, N.J., June 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., June 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition
PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the
Read more →SNGXSoligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results
PRINCETON, N.J., May 17, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rece
Read more →SNGXHyBryte™ Awarded Innovation Passport in the United Kingdom
PRINCETON, N.J., May 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that HyB
Read more →SNGXBroad Efficacy and Improved Safety Profile of HyBryte™ Presented at Society for Investigative Dermatology Virtual Meeting
PRINCETON, N.J., May 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Elle
Read more →SNGXSoligenix Presents at the National Foundation for Infectious Diseases Annual Conference on Vaccinology Research
PRINCETON, N.J., April 28, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXHyBryte™ Expanded Efficacy and Safety Data Presented at the American Academy of Dermatology Meeting
PRINCETON, N.J., April 26, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that E
Read more →SNGXSoligenix Announces Presentations at Prominent Scientific Conferences
PRINCETON, N.J., April 13, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today planne
Read more →SNGXSoligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCL
PRINCETON, N.J., April 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix Announces Recent Accomplishments And Year-End 2020 Financial Results
PRINCETON, N.J., March 30, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its re
Read more →SNGXSoligenix to Receive $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., March 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine
PRINCETON, N.J., March 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publica
Read more →SNGXSoligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter
PRINCETON, N.J., Feb. 24, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update
Read more →SNGXSoligenix to Present at the 2021 BIO CEO & Investor Digital Conference
PRINCETON, N.J., Feb. 11, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Investor Webcast Event: U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Jan. 19, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Jan. 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development
PRINCETON, N.J., Dec. 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today prelimi
Read more →SNGXSoligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing
PRINCETON, N.J., Dec. 16, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Demonstrates Extended Protection with its RiVax® Ricin Toxin Vaccine
PRINCETON, N.J., Dec. 8, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Recent Accomplishments And Third Quarter 2020 Financial Results
PRINCETON, N.J., Nov. 12, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rec
Read more →SNGXSoligenix Invited to Present at Upcoming Virtual Investor Conferences
PRINCETON, N.J., Nov. 10, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Oct. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that co
Read more →SNGXSoligenix to Present at the BIO Investor Forum
PRINCETON, N.J., Oct. 8, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its
Read more →SNGXSoligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens
PRINCETON, N.J., Sept. 15, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today public
Read more →SNGXSoligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine
PRINCETON, N.J., Sept. 10, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, released the presentat
Read more →SNGXSoligenix Announces Investor Webcast Event: Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine
PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix to Present at the LD Micro Conference
PRINCETON, N.J., Aug. 27, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results
PRINCETON, N.J., Aug. 14, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rec
Read more →SNGXSoligenix Announces Publication of Positive Pre-clinical Results for a Novel COVID-19 Vaccine
PRINCETON, N.J., July 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publica
Read more →SNGXSoligenix Issues Corporate Update - Highlights Important Catalysts for Second Half of 2020
PRINCETON, N.J., July 20, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update
Read more →SNGXSoligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis
PRINCETON, N.J., June 24, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has
Read more →SNGXSoligenix to Join Russell Microcap® Index
PRINCETON, N.J., June 22, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix to Present at the MedInvest Infectious Disease and Immunology Investor Conference
PRINCETON, N.J., June 9, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its
Read more →SNGXSoligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
PRINCETON, N.J., May 15, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rece
Read more →SNGXSoligenix Announces Publication of Correlates of Immune Protection for the RiVax® Ricin Toxin Vaccine
PRINCETON, N.J., May 11, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publicat
Read more →SNGXSoligenix Receives $840,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., May 7, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it h
Read more →SNGXSoligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
PRINCETON, N.J., April 30, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that c
Read more →SNGXSoligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals
PRINCETON, N.J., April 16, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has execute
Read more →SNGXSoligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
PRINCETON, N.J., April 6, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix Announces Recent Accomplishments And Year-End 2019 Financial Results
PRINCETON, N.J., March 30, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its re
Read more →SNGXSoligenix and University of Hawaiʻi at Mānoa Initiate Work on Novel Coronavirus Vaccine for COVID-19
PRINCETON, N.J., March 23, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXSoligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301 in Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., March 19, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positi
Read more →SNGXSoligenix Announces Successful Demonstration of Heat Stabilization for Filovirus Vaccine Platform
PRINCETON, N.J., Feb. 27, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXFDA Grants Soligenix "Fast Track" Designation for RiVax® in the Prevention of Ricin Poisoning
PRINCETON, N.J., Feb. 13, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces SGX301 Patient Case Study Presentation at the 4th World Congress of Cutaneous Lymphomas
PRINCETON, N.J., Feb. 11, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr
Read more →SNGXSoligenix Announces Japanese Patent Allowance for Use of Dusquetide in Oral Mucositis
PRINCETON, N.J., Feb. 3, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the
Read more →SNGXSoligenix to Present at the 22nd Annual BIO CEO & Investor Conference
PRINCETON, N.J., Jan. 30, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix - Advancing to Important
Soligenix - Advancing to Important With Two Pivotal Phase 3 Clinical Trials Company provides corporate update and Princeton, NJ - January 14, 2020 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and co
Read more →SNGXSoligenix - Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials
PRINCETON, N.J., Jan. 14, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update
Read more →SNGXSoligenix to Receive $850,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., Dec. 18, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine
PRINCETON, N.J., Dec. 12, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J., Dec. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has c
Read more →SNGXSoligenix to Present at the PCG Spotlight Series Conference
PRINCETON, N.J., Nov. 18, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results
PRINCETON, N.J., Nov. 12, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rec
Read more →SNGXSoligenix to Present at the 25th Annual BIO-Europe International Partnering Conference
PRINCETON, N.J., Nov. 6, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dan
Read more →SNGXSoligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition
PRINCETON, N.J., Oct. 24, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada
PRINCETON, N.J., Oct. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its
Read more →SNGXSoligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning
PRINCETON, N.J., Sept. 16, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXSoligenix Appoints Jonathan Guarino as Chief Financial Officer
PRINCETON, N.J., Sept. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXSoligenix Appoints Jonathan Guarino as Chief
Soligenix Appoints Jonathan Guarino as Chief executive with over two decades of financial and commercial business experience Princeton, NJ - September 11, 2019 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develo
Read more →SNGXSoligenix to Present at the RHK Capital 2019 Disruptive Growth Conference
PRINCETON, N.J., Aug. 29, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
PRINCETON, N.J., Aug. 28, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has
Read more →SNGXSoligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications
PRINCETON, N.J., Aug. 15, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results
PRINCETON, N.J., Aug. 13, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rec
Read more →SNGXSoligenix Announces Conference Presentations Demonstrating Formulations of Single and Multivalent Ebola Subunit Vaccines
PRINCETON, N.J., July 31, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that tw
Read more →SNGXSoligenix Receives European Patents for Oral BDP in the Treatment of Acute Radiation Injury of the Gastrointestinal Tract
PRINCETON, N.J., July 29, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix Announces Appointment of Diane L. Parks to its Board of Directors
PRINCETON, N.J., July 8, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appo
Read more →SNGXSoligenix to Present RiVax® Program at the 13ᵗʰ Annual CounterACT Network Research Symposium
PRINCETON, N.J., June 13, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr
Read more →SNGXSoligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents
PRINCETON, N.J., May 28, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Sol
Read more →SNGXSoligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results
PRINCETON, N.J., May 14, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rece
Read more →SNGXSoligenix -- Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials
PRINCETON, N.J., April 23, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update
Read more →SNGXSoligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer
PRINCETON, N.J., April 18, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXSoligenix Receives $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., April 15, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXSoligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942
PRINCETON, N.J., April 9, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix Receives US Patent for Dusquetide Related Analogs
PRINCETON, N.J., April 4, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix Announces Recent Accomplishments and Year-End 2018 Financial Results
PRINCETON, N.J., March 26, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its re
Read more →SNGXSoligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC
PRINCETON, N.J., March 18, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that t
Read more →SNGXSoligenix to Present at the Boston Oncology Investor Conference 2019
PRINCETON, N.J., March 11, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXSoligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®
PRINCETON, N.J., Feb. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the all
Read more →SNGXSoligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate
PRINCETON, N.J., Feb. 7, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publicat
Read more →SNGXSoligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs
PRINCETON, N.J., Jan. 23, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix to Receive $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., Dec. 11, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Publication of Scientific Review Discussing Clinical Applications of Innate Defense Regulator Technology
PRINCETON, N.J., Dec. 5, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publicat
Read more →SNGXSoligenix Selected to Present RiVax® Data at the Fourth International Conference on Vaccines Research & Development in Baltimore, Maryland
PRINCETON, N.J., Nov. 12, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr
Read more →SNGXSoligenix Announces Recent Accomplishments And Third Quarter 2018 Financial Results
PRINCETON, N.J., Nov. 9, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rece
Read more →SNGXSoligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J., Oct. 15, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has
Read more →SNGXAnnounces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment
Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma Princeton, NJ - October 15, 2018 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharm
Read more →SNGXSoligenix Announces Poster Presentations of its Ricin Vaccine and Dusquetide Oral Mucositis Programs at the 2018 NORD Rare Diseases and Orphan Products Breakthrough Summit
PRINCETON, N.J., Oct. 4, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXNIH selects Soligenix
PRINCETON, N.J., Sept. 13, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that t
Read more →SNGXSoligenix to Present at BioCentury
PRINCETON, N.J., Sept. 5, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Publication of Positive Long-Term Data Supporting Thermostability and Conformational Integrity of the RiVax® Ricin Toxin Vaccine
PRINCETON, N.J., Sept. 4, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publica
Read more →SNGXSoligenix to Present at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
PRINCETON, N.J., Aug. 29, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr
Read more →SNGXSoligenix Receives US Patent for Improved Production of Synthetic Hypericin
PRINCETON, N.J., Aug. 22, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix Announces Recent Accomplishments And Second Quarter 2018 Financial Results
PRINCETON, N.J., Aug. 8, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rece
Read more →SNGXSoligenix Announces a RiVax® Program Presentation at the 31st Annual Congress on Vaccines, Clinical Trials & B2B in Vancouver, Canada
PRINCETON, N.J., July 26, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr
Read more →SNGXPearson to its Board of Directors
Announces Appointment of Pearson to its Board of Directors NJ - July 24, 2018 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet m
Read more →SNGXSoligenix Announces Appointment of Mark Pearson to its Board of Directors
PRINCETON, N.J., July 24, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the app
Read more →SNGXDriving Towards Key Inflection Points
- Driving Towards Key Inflection Points Two Pivotal Phase 3 Clinical Trials provides mid-year update and guidance NJ - July 19, 2018 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing p
Read more →SNGXSoligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials
PRINCETON, N.J., July 19, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update
Read more →SNGXSoligenix Receives European and Canadian Patents for its Ricin Toxin Vaccine (RiVax®) Formulation
PRINCETON, N.J., July 9, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Closing of $8,000,000 At The Market Public Offering
PRINCETON, N.J., July 2, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the closing of its previously annou
Read more →SNGXSoligenix, Inc.
Soligenix, Inc. Prices $8,000,000 Public Offering At The Market Princeton, NJ - June 28, 2018 - Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical nee
Read more →SNGXSoligenix, Inc. Prices $8,000,000 Public Offering At The Market
PRINCETON, N.J., June 28, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced the pricing of an underwritten public of
Read more →SNGXSoligenix Announces Poster at the 2018 American Society of Microbiology Microbe Conference in Atlanta, Georgia
PRINCETON, N.J., June 4, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr.
Read more →SNGXSoligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results
PRINCETON, N.J., May 11, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rece
Read more →SNGXSoligenix to Present at the NYC Oncology Investor Conference 2018
PRINCETON, N.J., May 7, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its
Read more →SNGXSoligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin Poisoning
PRINCETON, N.J., March 22, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that t
Read more →SNGXSoligenix Announces Recent Accomplishments And Year-End 2017 Financial Results
PRINCETON, N.J., March 15, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its re
Read more →SNGXSoligenix to Present at the 12th Annual International Partnering Conference Bio-Europe Spring
PRINCETON, N.J., March 13, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXSoligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis
PRINCETON, N.J., Jan. 2, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the
Read more →SNGXSoligenix Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule
PRINCETON, N.J., Dec. 21, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that bi
Read more →SNGXSoligenix to Receive $417,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., Nov. 30, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CA
PRINCETON, N.J., Nov. 27, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr
Read more →SNGXSoligenix to Present at the 2017 Biotech and Money Showcase Conference
PRINCETON, N.J., Nov. 13, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 2nd Annual Superbugs & Superdrugs USA Conference
PRINCETON, N.J., Nov. 9, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ore
Read more →SNGXSoligenix Announces Recent Accomplishments And Third Quarter 2017 Financial Results
PRINCETON, N.J., Nov. 6, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rece
Read more →SNGXSoligenix Announces Closing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above Market
PRINCETON, N.J., Nov. 3, 2017 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Pricing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above Market
PRINCETON, N.J., Oct. 31, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that it has e
Read more →SNGXBroad-Spectrum Innate Defense Regulator Platform Technology to be Presented at the Peptide Therapeutics Foundation Symposium
PRINCETON, N.J., Oct. 24, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix to Present at the 3rd Annual Dawson James Small Cap Conference
PRINCETON, N.J., Oct. 17, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXDusquetide Technology Platform to be Presented at the 2nd World Congress and Expo on Immunology
PRINCETON, N.J., Oct. 5, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces $700,000 Subaward Supporting Development Collaboration on Thermostabilization of an Ebola Vaccine Candidate
PRINCETON, N.J., Sept. 25, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that S
Read more →SNGXSoligenix Announces $1.5 Million NIDCR SBIR Grant Award Supporting the Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
PRINCETON, N.J., Sept. 20, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that t
Read more →SNGXSoligenix Announces $1.5 Million NCI SBIR Grant Award Supporting the Pivotal Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Sept. 18, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that t
Read more →SNGXDusquetide as a Potential Solution to Antimicrobial Resistant Bacteria to be Presented at the 2017 World Anti-Microbial Resistance Congress
PRINCETON, N.J., Sept. 11, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXSoligenix to Present at the Rodman & Renshaw 19th Annual Global Investment Conference in New York City
PRINCETON, N.J., Sept. 7, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix to Present at the 8th Annual Investing for Cures Forum in New York City
PRINCETON, N.J., Sept. 5, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix, Inc. (Nasdaq: SNGX) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq:SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, will visit the Nasdaq MarketSite in Times Square. In
Read more →SNGXSoligenix Receives $2.5M in Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine
PRINCETON, N.J., Aug. 14, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix Announces Recent Accomplishments And Second Quarter 2017 Financial Results
PRINCETON, N.J., Aug. 11, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rec
Read more →SNGXSoligenix Initiates Pivotal Phase 3 Clinical Trial of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PRINCETON, N.J., July 27, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that pa
Read more →SNGXDusquetide Technology Platform to be Presented at the 2017 Drug Discovery and Therapy World Congress
PRINCETON, N.J., July 6, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine
PRINCETON, N.J., June 21, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXComplete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference
PRINCETON, N.J., June 19, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXNASDAQ: SNGX Rising to the Challenges of Rare Disease Treatment Forward - Looking Statements This presentation contains forward - looking statements . All statements other than statements of historical facts contained in
NASDAQ: SNGX Rising to the Challenges of Rare Disease Treatment Forward - Looking Statements This presentation contains forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our futu
Read more →SNGXSoligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
PRINCETON, N.J., May 18, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that lon
Read more →SNGXSoligenix Announces Recent Accomplishments And First Quarter 2017 Financial Results
PRINCETON, N.J., May 11, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rece
Read more →SNGXSoligenix Receives Japanese Patent for ThermoVax® Vaccine Heat Stabilization Platform Technology
PRINCETON, N.J., May 9, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it h
Read more →SNGXSoligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PRINCETON, N.J., May 3, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it h
Read more →SNGXEfficacy Results from Soligenix
PRINCETON, N.J., April 19, 2017 /PRNewswire/-- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that re
Read more →SNGXSoligenix to Present at the World Orphan Drug Congress
PRINCETON, N.J., April 12, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that M
Read more →SNGXSoligenix Announces Recent Accomplishments And Year-End 2016 Financial Results
PRINCETON, N.J., March 27, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its re
Read more →SNGXSoligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 19th Annual Superbugs & Superdrugs Conference
PRINCETON, N.J., March 15, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that O
Read more →SNGXSoligenix to Present Results from its Ricin Toxin Vaccine Program at the Society of Toxicology 56th Annual Meeting
PRINCETON, N.J., March 10, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that i
Read more →SNGXSoligenix Receives European Patent for Formulation of Synthetic Hypericin to Treat Psoriasis
PRINCETON, N.J., Feb. 22, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces SGX301 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
PRINCETON, N.J., Feb. 2, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today SGX301 (
Read more →SNGXNASDAQ: SNGX Rising to the Challenges of Rare Disease Treatment Forward - Looking Statements 2 This presentation contains forward - looking statements . All statements other than statements of historical facts contained
NASDAQ: SNGX Rising to the Challenges of Rare Disease Treatment Forward - Looking Statements 2 This presentation contains forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our fu
Read more →SNGXSoligenix to Present at 9th Annual Biotech Showcase Conference
PRINCETON, N.J., Jan. 6, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PRINCETON, N.J., Jan. 5, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the company had received posit
Read more →SNGXSoligenix Announces Extension of Development Agreement with Emergent BioSolutions
PRINCETON, N.J., Jan. 3, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Advances Collaboration with IDT Biologika
PRINCETON, N.J., Dec. 20, 2016 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Closing of Public Offering
PRINCETON, N.J., Dec. 16, 2016 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the closing of its previously anno
Read more →SNGXSoligenix Announces Closing of Public Offering Princeton, NJ
Soligenix Announces Closing of Public Offering Princeton, NJ, December 16, 2016 - Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced to
Read more →SNGXSoligenix, Inc. Prices $5,277,000 Public Offering and Completes Listing on Nasdaq
PRINCETON, N.J., Dec. 13, 2016 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the pricing of an underwritten pub
Read more →SNGXSoligenix Announces SGX942 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
PRINCETON, N.J., Dec. 12, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today SGX942 (
Read more →SNGXSoligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PRINCETON, N.J., Dec. 8, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the long-
Read more →SNGXSoligenix Announces Investor Webcast Event: Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis
PRINCETON, N.J., Dec. 8, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it w
Read more →SNGXAnnounces Positive Long-Term Follow-up Results from its
Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients data supports advancing development to pivotal Phase 2b/3 program NJ - December 8, 2016 - Soligenix, Inc. (OTCQB: SNGX
Read more →SNGXSoligenix Announces Recent Accomplishments and Third Quarter 2016 Financial Results Highlighted by Revenues of $3.0 Million
PRINCETON, N.J., Nov. 10, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rece
Read more →SNGXSoligenix Receives European Medicines Agency Designation as Small and Medium Enterprise
PRINCETON, N.J., Oct. 25, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Publication of its Phase 2 Clinical Trial Results of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PRINCETON, N.J., Oct. 18, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the pub
Read more →SNGXSoligenix to Receive $530,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., Oct. 17, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Poster Presentations from its Gastrointestinal Acute Radiation Syndrome Program at the 2016 Radiation Research Society Meeting
PRINCETON, N.J., Oct. 13, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Poster Presentation of its Ricin Vaccine and Dusquetide Orphan Programs at the 2016 NORD Rare Diseases and Orphan Products Breakthrough Summit
PRINCETON, N.J., Oct. 11, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Announces Reverse-Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital Market
PRINCETON, N.J., Oct. 7, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXAnnounces Reverse-Split in Preparation for Proposed
Announces Reverse-Split in Preparation for Proposed of its Common Stock to the NASDAQ Capital Market NJ - October 7, 2016 - Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
Read more →SNGXSoligenix to Present at 2016 Aegis Growth Conference
PRINCETON, N.J., Sept. 15, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ch
Read more →SNGXSoligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis
PRINCETON, N.J. and FOSTER CITY, Calif., Sept. 12, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, and SciClone Pharmaceutica
Read more →SNGXSoligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs
Princeton, N. J., Sept. 6, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXFDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
PRINCETON, N.J., Aug. 18, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the
Read more →SNGXSoligenix Announces Recent Accomplishments and Second Quarter 2016 Financial Results Highlighted by Revenues of $3.2 Million
PRINCETON, N.J., Aug. 11, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rece
Read more →SNGXSoligenix Receives Additional BARDA and NIAID Funding to Advance Development of OrbeShield® in GI ARS
PRINCETON, N.J., July 25, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the Bio
Read more →SNGXSoligenix Announces Presentation of Positive Preliminary Results of a Heat Stable Ebola Vaccine Formulation
PRINCETON, N.J., July 18, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive
Read more →SNGXOTC QB: SNGX Rising to the Challenges of Rare Disease Treatment Forward - Looking Statements This presentation contains forward - looking statements . All statements other than statements of historical facts contained in
OTC QB: SNGX Rising to the Challenges of Rare Disease Treatment Forward - Looking Statements This presentation contains forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our futu
Read more →SNGXSoligenix Appoints Karen Krumeich, as Chief Financial Officer
PRINCETON, N.J., June 20, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it
Read more →SNGXSoligenix Develops Defenses Against Bioterrorism
SAN FRANCISCO, CA--(Marketwired - June 16, 2016) - Maxim Group biotech analyst Jason Kolbert notes "steady progress" is being made by Soligenix Inc., a small-cap biotech with programs addressing bioterrorism threats and a devastating side effect of cancer treatment, in his Q1/16
Read more →SNGXSoligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference
PRINCETON, N.J., June 6, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it w
Read more →SNGXFDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis
PRINCETON, N.J., May 31, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its
Read more →SNGXSoligenix to Present at the 2016 Marcum MicroCap Conference
PRINCETON, N.J., May 26, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Pres
Read more →SNGXSoligenix Announces Recent Accomplishments and First Quarter 2016 Financial Results
PRINCETON, N.J., May 12, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recen
Read more →SNGXSoligenix Inc.'s CEO Dr. Christopher Schaber Interviewed by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - April 28, 2016) - With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. Two candidates targetin
Read more →SNGXSoligenix Announces Issuance of New Patents for Dusquetide
PRINCETON, N.J., April 14, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that th
Read more →SNGXSoligenix Announces Publication of Preclinical Efficacy Results with Dusquetide in Infectious Disease
PRINCETON, N.J., March 29, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the pub
Read more →SNGXSoligenix Announces Recent Accomplishments and Year-End 2015 Financial Results
PRINCETON, N.J., March 24, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its rec
Read more →SNGXSoligenix to Present at Source Capital Group
PRINCETON, N.J., Feb. 2, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Chri
Read more →SNGXSoligenix Provides 2016 Business Outlook
PRINCETON, N.J., Jan. 26, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its 2016
Read more →SNGXSoligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PRINCETON, N.J., Dec. 16, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive
Read more →SNGXSoligenix Will Host a Conference Call to Update Shareholders on Recent Positive Clinical Results and Company Development Milestones
PRINCETON, N.J., Dec. 16, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that it will h
Read more →SNGXSoligenix Announces Initiation of its Pivotal Phase 3 Clinical Trial of SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Dec. 14, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that pat
Read more →SNGXSoligenix Receives $490,000 in Non-Dilutive Financing from New Jersey
PRINCETON, N.J., Dec. 9, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it h
Read more →SNGXSoligenix Provides Clinical Program Updates for December 2015
PRINCETON, N.J., Dec. 4, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the follo
Read more →SNGXSoligenix Announces Recent Highlights and Third Quarter 2015 Financial Results
PRINCETON, N.J., Nov. 12, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today recent h
Read more →SNGXSoligenix to Present at the 3rd Annual BioNJ CEO Summit
PRINCETON, N.J., Oct. 5, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its
Read more →SNGXSoligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PRINCETON, N.J., Aug. 31, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has compl
Read more →SNGXSoligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS
PRINCETON, N.J., Aug. 27, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the Nat
Read more →SNGXSoligenix Announces Collaboration with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., June 23, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will
Read more →SNGXSoligenix Announces Publication of Successful Application of its Heat Stabilization Technology to a Human Papillomavirus Vaccine
PRINCETON, N.J., June 2, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publicati
Read more →SNGXSoligenix Announces Collaboration with the University of Hawai
PRINCETON, N.J., May 28, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today a collaborati
Read more →SNGXSoligenix Announces First Quarter 2015 Highlights and Financial Results
PRINCETON, N.J., May 14, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent highli
Read more →SNGXSoligenix Announces Development Agreement with Emergent BioSolutions
PRINCETON, N.J., May 13, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has i
Read more →SNGXSoligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO
PRINCETON, N.J., May 4, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will b
Read more →SNGXSoligenix Announces FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX203 in Pediatric Crohn
PRINCETON, N.J., April 14, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that agreem
Read more →SNGXSoligenix Inc.'s CEO Christopher Schaber Interviewed by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - Apr 9, 2015) - Orphan diseases associated with inflammation present excellent development opportunities for small biopharmaceutical companies and their investors. Additionally, inflammatory conditions can result from treatment with cancer therape
Read more →SNGXSoligenix Announces Recent Accomplishments and Year-End 2014 Financial Results
PRINCETON, N.J., March 24, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent acco
Read more →SNGXSoligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine
PRINCETON, N.J., March 11, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publica
Read more →SNGXSoligenix to Present at the 27th Annual ROTH Conference
PRINCETON, N.J., March 5, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today
Read more →SNGXSoligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PRINCETON, N.J., March 3, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has recei
Read more →SNGXRicin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PRINCETON, N.J., Feb. 13, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it pres
Read more →SNGXPreclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PRINCETON, N.J., Feb. 11, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it pres
Read more →SNGXSoligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City
PRINCETON, N.J., Feb. 5, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today
Read more →SNGXSoligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PRINCETON, N.J., Feb. 2, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will
Read more →SNGXSoligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine
PRINCETON, N.J., Jan. 29, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publicat
Read more →SNGXFDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Jan. 7, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX3
Read more →SNGXSoligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome
PRINCETON, N.J., Jan. 5, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that prelimin
Read more →SNGXSoligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data
PRINCETON, N.J., Dec. 29, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publicat
Read more →SNGXSoligenix Announces Closing of Public Offering of Units
PRINCETON, N.J., Dec. 24, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on Dece
Read more →SNGXSoligenix Announces Pricing of Public Offering of Units
PRINCETON, N.J., Dec. 19, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the pricing
Read more →SNGXSoligenix Receives $617,000 in Non-Dilutive Financing from New Jersey
PRINCETON, N.J., Dec. 11, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense announced today that it has r
Read more →SNGXSoligenix Appoints Oreola Donini, PhD, as Chief Scientific Officer
PRINCETON, N.J., Dec. 10, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the appointm
Read more →SNGXSoligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board
PRINCETON, N.J., Nov. 17, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the formatio
Read more →SNGXSoligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301, Synthetic Hypericin, for the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Nov. 10, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today its financia
Read more →SNGXSoligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
PRINCETON, N.J., Sept. 23, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has
Read more →SNGXSoligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine
PRINCETON, N.J., Sept. 19, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has
Read more →SNGXSoligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that agreem
Read more →SNGXSoligenix Announces Issuance of US Patent for ThermoVax™ Technology
PRINCETON, N.J., Sept. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the US
Read more →SNGXSoligenix to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
PRINCETON, N.J., Sept. 8, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its Pre
Read more →SNGXSoligenix Expands Pipeline with Acquisition of Phase 3-Ready Oncology Clinical Program
PRINCETON, N.J., Sept. 5, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisit
Read more →SNGXSoligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine
PRINCETON, N.J., Sept. 2, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developi
Read more →SNGXSoligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments
PRINCETON, N.J., Aug. 11, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developi
Read more →SNGXSoligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax™
PRINCETON, N.J., Aug. 7, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developin
Read more →SNGXSoligenix Announces Combination Vaccine for Ricin and Anthrax Achieves Simultaneous Protection
PRINCETON, N.J., July 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developin
Read more →SNGXSoligenix Reports First Quarter 2014 Financial Results, and Highlights Recent Accomplishments
PRINCETON, N.J., May 12, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developin
Read more →SNGXSoligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
PRINCETON, N.J., April 7, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developi
Read more →SNGXSoligenix Reports Year-End 2013 Financial Results and Highlights Recent Accomplishments
PRINCETON, N.J., March 26, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as develop
Read more →SNGXSoligenix to Present at 2014 World Vaccine Congress in Washington, DC
PRINCETON, N.J., March 11, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical n
Read more →SNGXSoligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PRINCETON, N.J., Feb. 14, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developi
Read more →SNGXSoligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City
PRINCETON, N.J., Feb. 5, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developin
Read more →SNGXSoligenix Receives $750,000 in Non-Dilutive Financing from New Jersey
PRINCETON, N.J., Jan. 16, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developin
Read more →SNGXSoligenix Announces Positive One-Year High-Temperature Stability Results with ThermoVax™ Vaccine Heat Stabilization Technology
PRINCETON, N.J., Jan. 15, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developi
Read more →SNGXSoligenix to Present at the 2014 Biotech Showcase in San Francisco
PRINCETON, N.J., Jan. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developin
Read more →SNGXSoligenix Appoints Richard Straube, MD, as Chief Medical Officer
PRINCETON, N.J., Jan. 6, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developin
Read more →SNGXSoligenix Announces Initiation of a Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PRINCETON, N.J., Dec. 5, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developin
Read more →SNGXSoligenix Announces Initiation of a Phase 2 Clinical Trial of orBec® for the Treatment of Chronic GI GVHD
PRINCETON, N.J., Dec. 2, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developin
Read more →SNGXSoligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
PRINCETON, N.J., Nov. 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developi
Read more →SNGXSoligenix Reports Third Quarter 2013 Financial Results, and Highlights Recent Accomplishments
PRINCETON, N.J., Nov. 12, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developi
Read more →SNGXSoligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
PRINCETON, N.J., Oct. 31, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an u
Read more →SNGXSoligenix to Host Conference Call and Webcast Discussion on Oral Mucositis
PRINCETON, N.J., Oct. 28, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet me
Read more →SNGXSoligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
PRINCETON, N.J., Oct. 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet me
Read more →SNGXSoligenix Announces Formation of International Melioidosis Scientific Advisory Board
PRINCETON, N.J., Oct. 17, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet me
Read more →SNGXSoligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
PRINCETON, N.J., Oct. 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet med
Read more →SNGXSoligenix Awarded NIAID Contract Valued up to $6.4 Million for the Development of OrbeShield™ in GI ARS
PRINCETON, N.J., Sept. 25, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an
Read more →SNGXSoligenix Awarded BARDA Contract Valued up to $26.3 Million for Advanced Development of OrbeShield™ in GI ARS
PRINCETON, N.J., Sept. 19, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an
Read more →SNGXFDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
PRINCETON, N.J., Sept. 16, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical n
Read more →SNGXSoligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
PRINCETON, N.J., Sept. 5, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical ne
Read more →SNGXSoligenix Reports Second Quarter 2013 Financial Results, and Highlights Recent Accomplishments
PRINCETON, N.J., Aug. 12, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical ne
Read more →SNGXSoligenix Announces Commercial Collaboration with SciClone Pharmaceuticals in China for SGX942 in the Treatment of Oral Mucositis
PRINCETON, N.J., July 8, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical nee
Read more →SNGXSoligenix Completes Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn
PRINCETON, N.J., June 28, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical ne
Read more →SNGXSoligenix Closes $7.1 Million Public Offering
PRINCETON, N.J., June 26, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medica
Read more →SNGXSoligenix Closes $7.1 Million Public Offering Princeton, NJ
Soligenix Closes $7.1 Million Public Offering Princeton, NJ - June 26, 2013 - Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures whe
Read more →SNGXSoligenix Announces Pricing of Public Offering
Soligenix Announces Pricing of Public Offering of Common Stock and Warrants Princeton, NJ - June 21, 2013 - Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and
Read more →SNGXSoligenix Announces Pricing of Public Offering of Common Stock and Warrants
PRINCETON, N.J., June 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medica
Read more →SNGXFDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
PRINCETON, N.J., June 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that its SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy
Read more →SNGXSoligenix Announces Issuance of US Patent for its ThermoVax™ Technology
PRINCETON, N.J., May 22, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical nee
Read more →SNGXSoligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn
PRINCETON, N.J., May 15, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical nee
Read more →SNGXSoligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
PRINCETON, N.J., May 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need
Read more →SNGXSoligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
PRINCETON, N.J. and GERMANTOWN, Md., May 1, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, annou
Read more →SNGXSoligenix to Present at World Vaccine Congress & Expo
PRINCETON, N.J., April 16, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products for serious inflammatory diseases and biodefense countermeasures where there remains an unmet medica
Read more →SNGXSoligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis
PRINCETON, N.J., March 27, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND
Read more →SNGXSoligenix Announces Significant Progress with ThermoVax™ Towards the Development of Heat Stable Vaccines
PRINCETON, N.J., March 19, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today key progress in the development of ThermoVax™, its proprietary vaccine thermostabilization technology. Several com
Read more →SNGXSoligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
PRINCETON, N.J., Feb. 26, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the year ended December 31, 2012. Soligenix's revenues for the year ended December 31
Read more →SNGXSoligenix Submits BARDA Contract Proposal for Development of OrbeShield™ in GI ARS
PRINCETON, N.J., Feb. 20, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today submission of a full contract proposal to the Biomedical Advanced Research and Development Authority (BARDA) Div
Read more →SNGXSoligenix to Present at 15th Annual BIO CEO & Investor Conference
PRINCETON, N.J., Feb. 8, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation a
Read more →SNGXSoligenix Announces Formation of Oral Mucositis Medical Advisory Board
PRINCETON, N.J., Feb. 4, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development-stage biopharmaceutical company, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as
Read more →SNGXFDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
PRINCETON, N.J., Jan. 29, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its OrbeShieldTM (oral beclomethasone 17,21-dipropionate or oral BDP) development program for the treatment
Read more →SNGXBARDA Invites Soligenix to Submit Contract Proposal for Development of OrbeShield™ in GI ARS
PRINCETON, N.J., Jan. 7, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that pursuant to review of the Company's white paper on development of OrbeShield™ as a countermeasure for the ga
Read more →SNGXSoligenix Receives IND Clearance from FDA to Initiate Program Evaluating OrbeShieldTM as a Therapy for Gastrointestinal Acute Radiation Syndrome
PRINCETON, N.J., Jan. 4, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IN
Read more →SNGXFDA Grants Soligenix Orphan Drug Designation for OrbeShield™ for Treatment after Exposure to a Radiological Disaster
PRINCETON, N.J., Jan. 2, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan dr
Read more →SNGXSoligenix Receives $521,000 in Non-Dilutive Financing from New Jersey
PRINCETON, N.J., Dec. 28, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has recently received approximately $521,000, net of transaction costs, in non-dilutive financing via th
Read more →SNGXSoligenix Regains North American and European Commercial Rights to Oral BDP
PRINCETON, N.J., Dec. 27, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, today announced that it has regained the North American and European commercial rights to oral BDP (beclomethasone 17.21-dipropi
Read more →SNGXSoligenix Expands Pipeline with Acquisition of Novel Innate Defense Regulator Clinical Program
PRINCETON, N.J., Dec. 18, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today the acquisition of a novel drug technology, known as SGX94, representing a unique approach to modulation of the
Read more →SNGXSoligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
PRINCETON, N.J., Nov. 14, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the third quarter ended September 30, 2012. Soligenix's revenues for the quarter ende
Read more →SNGXFDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohn
PRINCETON, N.J., Nov. 8, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its program for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction
Read more →SNGXSoligenix Announces Formation of Acute Radiation Syndrome Scientific Advisory Board
PRINCETON, N.J., Oct. 3, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today the formation of a Scientific Advisory Board (SAB) to provide strategic guidance to the Company as it relates to
Read more →SNGXSoligenix Announces Presentation of OrbeShield™ Data at Annual Radiation Research Society Meeting
PRINCETON, N.J., Oct. 1, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that results of a study in a canine model of OrbeShieldTM (oral beclomethasone 17,21-dipropionate) will be presen
Read more →SNGXSoligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
PRINCETON, N.J., Sept. 13, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the company), a development stage biopharmaceutical company announced today that the US Patent Office granted patent 8,263,582 entitled "Method of Treating Inflammatory Disorders of the Ga
Read more →SNGXSoligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX203 as Therapy for Pediatric Crohn
PRINCETON, N.J., Sept. 6, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (I
Read more →SNGXSoligenix Announces $300,000 NCI SBIR Grant Award Supporting a Phase 2 Trial of orBec® as a Treatment for Chronic GI GVHD
PRINCETON, N.J., Sept. 4, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the National Cancer Institute (NCI) has awarded Soligenix a Small Business Innovation Research (SBIR) grant
Read more →SNGXSoligenix Announces Positive Phase 1B Clinical Results with RiVax™, its Vaccine Against Ricin Toxin Exposure
PRINCETON, N.J., Aug. 30, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today the results of a Phase 1B clinical trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax™, desig
Read more →SNGXSoligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
PRINCETON, N.J., Aug. 10, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the second quarter ending June 30, 2012. Soligenix's revenues for the quarter ending
Read more →SNGXSoligenix Announces $600,000 NIAID SBIR Grant Award Supporting Further Evaluation of OrbeShield™ as a Treatment for Acute Radiation Syndrome
PRINCETON, N.J., July 17, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business In
Read more →SNGXSoligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
PRINCETON, N.J., June 27, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of Seattle, WA to
Read more →SNGXSoligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
PRINCETON, N.J., May 14, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the quarter ending March 31, 2012. Soligenix's revenues for the quarter ending March 3
Read more →SNGXSoligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
PRINCETON, N.J., April 25, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today further progress in the development of ThermoVax™, its proprietary vaccine thermostabilization technology. Prog
Read more →SNGXSoligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
PRINCETON, N.J., March 27, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the year ended December 31, 2011. Soligenix's revenues for the year ended December 3
Read more →SNGXSoligenix Announces Positive Survival Results of SGX202 in Radiation Injury
PRINCETON, N.J., Feb. 21, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced today further promising preliminary results from its continuing preclinical study of SGX202 (oral beclomethasone dipr
Read more →SNGXSoligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
PRINCETON, N.J., Feb. 10, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced preliminary results today from a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclo
Read more →SNGXSoligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology
PRINCETON, N.J., Feb. 6, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Solig
Read more →SNGXSoligenix Announces 1 for 20 Reverse-Split of its Common Stock
PRINCETON, N.J., Feb. 1, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a one-fo
Read more →SNGXSoligenix Receives $574,000 in Non-Dilutive Financing from New Jersey
PRINCETON, N.J., Jan. 26, 2012 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has recently received approximately $574,000, net of transaction costs, in non-dilutive fin
Read more →SNGXSoligenix Demonstrates Robust Stability Results with its SGX204 Anthrax Vaccine
PRINCETON, N.J., Jan. 18, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from long-term stability studies of its proprietary DNI (dominant negative inhibitor) anthrax rPA (recom
Read more →SNGXSoligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
PRINCETON, N.J., Dec. 15, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option
Read more →SNGXSoligenix Announces Publication of Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
PRINCETON, N.J., Dec. 12, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of o
Read more →SNGXSoligenix Reports Third Quarter 2011 Financial Results
PRINCETON, N.J., Nov. 14, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011. Soligenix's revenues for the third quarter of 2011 were ap
Read more →SNGXSoligenix Announces Formation of Pediatric Crohn
PRINCETON, N.J., Oct. 11, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it rel
Read more →SNGXSoligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
PRINCETON, N.J., Sept. 15, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced that an independent Data Safety Monitoring Board (DSMB) recently completed a pre-specified interim analysis for safety and f
Read more →SNGXSoligenix Reports Second Quarter 2011 Financial Results and Reviews Accomplishments
PRINCETON, N.J., Aug. 12, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2011. Soligenix’s revenues for the second quarter of 2011 were approxi
Read more →SNGXSoligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
PRINCETON, N.J., July 28, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) for
Read more →SNGXSoligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
PRINCETON, N.J., June 27, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a late-stage biopharmaceutical company, announces the appointment of Jerome Zeldis, MD, PhD, Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Cel
Read more →SNGXSoligenix Appoints Joseph Warusz as Vice President of Administration and Controller
PRINCETON, N.J., June 2, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it recently appointed Joseph Warusz as its new Vice President of Administration and Controller. In this role, Mr. W
Read more →SNGXSoligenix Reports First Quarter 2011 Financial Results and Reviews Accomplishments
PRINCETON, N.J., May 13, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2011. Soligenix's revenues for the first quarter of 2011 were approximat
Read more →SNGXSoligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
PRINCETON, N.J., March 29, 2011 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the year ended December 31, 2010. Soligenix's revenues for the year ended Dece
Read more →SNGXSoligenix to Present at 13th Annual BIO CEO & Investor Conference
PRINCETON, N.J., Feb. 9, 2011 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presenta
Read more →SNGXSoligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
PRINCETON, N.J., Feb. 1, 2011 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it has appointed Kevin Horgan, MD, as its Senior Vice President and Chief Medical Officer. Dr. Horgan
Read more →SNGXSoligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
PRINCETON, N.J., Jan. 27, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, today announced that it has entered into a definitive license agreement with the University of Colorado (CU) for novel tec
Read more →SNGXSoligenix Receives $245,810 in Non-Dilutive Financing from New Jersey
PRINCETON, N.J., Jan. 25, 2011 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it has recently received $245,810, net of transaction costs, in non-dilutive financing via the State
Read more →SNGXSoligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
PRINCETON, N.J., Jan. 20, 2011 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to RiVax™ for the preve
Read more →SNGXSoligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
PRINCETON, N.J., Jan. 18, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, announced today promising preliminary results from a preclinical study of SGX202 (oral beclomathasone dipropionate or BDP)
Read more →SNGXSoligenix Announces Issuance of United States Patent for RiVax™, its Vaccine Against Ricin Toxin
PRINCETON, N.J., Nov. 22, 2010 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) has granted patent #7,829,668, entitled "Compos
Read more →SNGXSoligenix Reports Third Quarter 2010 Financial Results and Reviews Accomplishments
PRINCETON, N.J., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the third quarter of 2010. Soligenix's revenues for the third quarter
Read more →SNGXSoligenix Receives Award Totaling $244,479 for orBec® Program From Qualifying Therapeutic Discovery Project
PRINCETON, N.J., Nov. 3, 2010 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, announced today that the Company has been awarded a cash grant totaling $244,479 under the U.S. Internal Revenue Service's
Read more →SNGXSoligenix Announces Completion of Enrollment and Preliminary Safety Results of a Phase 1B Clinical Trial for RiVax™
PRINCETON, N.J., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, reported today that it has completed enrollment of its Phase 1B clinical trial of RiVax™, a ricin subunit vaccine
Read more →SNGXSoligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
PRINCETON, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec® for the pr
Read more →SNGXSoligenix Provides Corporate Update Announces Election of Tamar D. Howson and Virgil D. Thompson to its Board of Directors Princeton, NJ
Soligenix Provides Corporate Update Announces Election of Tamar D. Howson and Virgil D. Thompson to its Board of Directors Princeton, NJ - September 27, 2010 - Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a late-stage biopharmaceutical company, announced the resul
Read more →SNGXSoligenix Provides Corporate Update
PRINCETON, N.J., Sept. 27 /PRNewswire-FirstCall/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, announced the results of its recent meeting of shareholders as well as an adjustment to the expected timeline to comp
Read more →SNGXSoligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
PRINCETON, N.J., Sept. 13 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, announced today that its President and Chief Executive Officer Christopher J. Schaber, Ph.D. will present a company overview hi
Read more →SNGXSoligenix Announces Publication of Article Identifying Domains Within the Ricin Toxin A Subunit as Targets of Protective Antibodies
PRINCETON, N.J., Sept. 2 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today the publication of an article online in Vaccine. The article describes the systematic identification o
Read more →SNGXSoligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
PRINCETON, N.J., Aug. 23 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Pro
Read more →SNGXSoligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
PRINCETON, N.J., Aug. 13 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010. Soligenix’s revenues for the second quarter of
Read more →SNGXSoligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments Princeton, NJ
Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments Princeton, NJ - May 17, 2010 - Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 201
Read more →SNGXSoligenix Reports Year-End 2009 Financial Results and Reviews Accomplishments Princeton, NJ
Reports Year-End 2009 Financial Results and Princeton, NJ - April 1, 2010 - Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, today announced its financial results for revenues for the year ended December 31, 2009 were $2,816,03
Read more →SNGXSOLIGENIX PRESS RELEASE 3Q 09 ex99_1.htm [SOLIGENIX Logo] Soligenix Reports Third Quarter 2009 Financial Results Princeton, NJ
Soligenix Reports Third Quarter 2009 Financial Results Princeton, NJ - November 13, 2009 - Soligenix, Inc., (Soligenix or the Company) (OTC BB: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today its financial results for the third q
Read more →SNGXSoligenix Announces Initiation of its Confirmatory Phase 3 Clinical Trial of orBec in Acute GI GVHD Receives $1 Million Milestone Payment under Sigma-Tau Collaboration Agreement Princeton, NJ
Soligenix Announces Initiation of its Confirmatory Phase 3 Clinical Trial of orBec in Acute GI GVHD Receives $1 Million Milestone Payment under Sigma-Tau Collaboration Agreement Princeton, NJ - October 15, 2009 - Soligenix, Inc., (Soligenix or the Company) (OTC BB: SNGX), forme
Read more →SNGX(Soligenix, Inc. Logo) Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors Princeton, NJ
(Soligenix, Inc. Logo) Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors Princeton, NJ - October 9, 2009 - Soligenix, Inc. (Soligenix or the Company), (OTC BB: SNGX), a late-stage biopharmaceutical company, announced today that Robert J. Rubin, MD, has been appo
Read more →SNGXDOR BioPharma, Inc. 29 Emmons Drive, Suite C-10 Princeton, NJ 08540 www.dorbiopharma.com DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines Grant Supports Advancement
29 Emmons Drive, Suite C-10 www.dorbiopharma.com DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines Grant Supports Advancement of DOR's Ricin Toxin Vaccine RiVaxTM Princeton, NJ - September 21, 2009 - DOR BioPharma, Inc.
Read more →SNGXDOR BioPharma, Inc. 29 Emmons Drive, Suite C-10 Princeton, NJ 08540 www.dorbiopharma.com DOR BioPharma Reports 2 nd Quarter and 1 st Half 2009 Financial Results and Reviews Recent Accomplishments Princeton, NJ
29 Emmons Drive, Suite C-10 www.dorbiopharma.com DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments Princeton, NJ - August 14, 2009 - DOR BioPharma, Inc. (OTC BB: DORB) (DOR or the Company), a late-stage biopharmaceutical c
Read more →Competitive Position
How SNGX ranks across every disease it competes inCompetitive Position is a premium feature
See how SNGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial